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A rabbit went to a small village shop and asked: 
“Do you have any cabbages or carrots?” 
“No, unfortunately we don’t,” the seller replied. 
The rabbit returned the next day. 
“Do you have any cabbages or carrots?” it asked. 
To which the seller replied: “No, we don’t.” 
 
The rabbit kept coming back to the shop 
for the cabbages and carrots every day, with no success. 
The seller grew more and more irritated, until finally, 
in a state of extreme angriness, he threatened the rabbit: 
“If you come here once more to inquire about cabbages or carrots, 
I will nail your ears to the wall!” 
 
The next day the rabbit returned to the shop again and asked: 
“Do you have any hammers or nails?” 
“No, we don’t,” the seller replied. 
And the rabbit asked: 
“Then, do you have any cabbages or carrots?” 
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ABSTRACT 
 
The complement system is a network of over 30 plasma proteins that act in, for 
example, protecting the body against invading microbes and removing damaged self 
cells. Complement activation proceeds in a cascade-like fashion, resulting in deposition 
of certain protein fragments on cell surfaces and liberation of others to the fluid nearby. 
Due to the destructive nature of complement attacks, it is imperative that this system 
be stringently controlled.  
When regulation fails, deleterious complement activation on self cells follows. This is 
the case for example in atypical hemolytic uremic syndrome (aHUS), a rare thrombotic 
microangiopathy characterized by hemolysis, thrombocytopenia and renal 
impairment. In roughly two thirds of aHUS patients, abnormalities in complement 
genes can be detected. A frequent observation is a mutation in the regulator factor H 
(FH). The majority of FH mutations in aHUS cluster in the two C-terminal domains of 
the protein, i.e. FH19-20. These are critical for directing FH onto cell surfaces under 
complement attack. Several important aspects of the syndrome have been uncovered, 
but the mechanisms underlying aHUS pathogenesis remain incompletely understood. 
The general aim of this work was to better explain the molecular events leading to 
aHUS. First it was asked, whether disturbances in the recently described interactions 
between FH19-20 and malondialdehyde (MDA) adducts could be involved in aHUS. To 
study this, binding assays employing MDA-modified proteins and wt and mutant FH19-
20 fragments were performed. FH19-20 binding was observed only if a high density of 
MDA adducts on the surface was present. Since such extensive MDA modification of cell 
surface proteins is improbable in vivo, it was concluded that disturbed recognition of 
MDA adducts on cells by FH is unlikely to be relevant in aHUS. 
Next, the hypothesis of plasminogen to regulate propagation of the complement 
cascade on cell surfaces was tested. Serum complement was activated on erythrocytes, 
endothelial cells, and platelets with or without added plasminogen, and complement 
activation determined as cell lysis or deposition of C5b-9 or C3b. Plasminogen was 
observed to cause only a very minor inhibition of complement activation on platelets. 
It was concluded that reduced complement control by plasminogen does not properly 
explain the recent association of plasminogen deficiency with aHUS.  
The final aim of this work was to determine the role of sialic acid in FH-mediated 
regulation on not only erythrocytes, but also on endothelial cells and platelets. To this 
end, the abilities of several FH19-20 fragments carrying aHUS-associated mutations to 
antagonize FH function on different types of cells was compared. Flow cytometry 
detection of FH binding and C3b deposition revealed identical patterns of FH19-20 
function on all types of cells. Removal of sialic acid from cells impaired FH function on 
them. With the help of recent structural data, it was concluded that mutations impair 
simultaneous binding of the C-terminus of FH to surface sialic acid and C3b, providing 
a unifying explanation for association between the C-terminus mutations of FH and the 
clinical disease aHUS.  
In conclusion, the work presented in this thesis improves our understanding of the 
pathogenic mechanisms involved in aHUS. Most importantly, the results show that in 
aHUS, the underlying common defect of various FH C-terminus mutations is the 
inability to simultaneously bind sialic acid and C3b on cells under complement attack.  
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1 INTRODUCTION 
A pale young man arrives at the emergency room of the Haartman hospital late in the 
evening. He reports abdominal and back pain, and keeps vomiting. He has also suffered 
from a diarrhea for four days, and seems to have a little shortness of breath. 
Preliminary blood tests are requested by the young medical doctor who examines the 
patient. Creatinine level is observed to be slightly elevated, although dehydration is not 
evident. The platelet count and hemoglobin concentration are somewhat below the 
lower normal limit. The patient is admitted to a ward with the diagnosis of 
gastroenteritis. He is given intravenous isotonic saline as a supportive treatment 
during the night. The hydration state is carefully monitored, because the elevated 
creatinine level hints to disturbances in renal function. 
Next morning, urine output is found to be low and the blood pressure is observed to 
have increased. Diarrhea is no longer a problem, but the routine blood tests reveal the 
platelet count to have further decreased. Therefore the patient is transferred to the 
Meilahti Hospital for further examinations. On admission to this referral hospital, the 
creatinine concentration is found to be very high. Also, the patient has stopped 
urinating. Further tests indicate kidney failure and therefore dialysis is started. 
Hemoglobin level has further dropped and is alarmingly 
low. A nearly complete absence of haptoglobin, the 
detoxifier of hemoglobin in plasma, is detected. This and the 
clearly elevated level of plasma lactate dehydrogenase 
together suggest hemolysis. Coombs test gives a negative 
result, ruling out autoimmune attack as the cause of 
hemolysis. Microscopy of blood smear reveals schistocytes 
and fragmented erythrocytes in blood. This, together with 
the observed thrombocytopenia and renal failure, suggest 
the diagnosis of hemolytic uremic syndrome (HUS). Thus, 
plasma exchange (Fig. 1) is started.  
Because the patient initially presented with diarrhea, the 
typical form of HUS is suspected. A stool sample is taken to 
be tested for the HUS-causing bacterium, the shiga-toxin 
producing enterohemorrhagic Escherichia coli (EHEC). The 
result arrives after two days, and is negative for EHEC. This 
indicates that the right diagnosis is the atypical form of HUS 
(aHUS). aHUS is usually associated with excessive 
complement activation, and patient samples are analyzed 
for complement abnormalities. Sequencing reveals a 
mutation in the gene of the complement regulator factor H. 
Therapeutic complement inhibition with the drug 
eculizumab cannot, however, be started due to its 
extremely high cost, and thus only plasma treatments can 
be given. Nevertheless, the patient recovers. 
Figure 1.  Plasma  exchange equip- 
ment (Copyright Terumo BCT Incor- 
porated.   Used  with   permission).             
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2 LITERATURE REVIEW 
Atypical hemolytic uremic syndrome (aHUS) is a serious, life-threatening disease. As a 
thrombotic microangiopathy, it features for example formation of fibrin rich thrombi 
in the vasculature, suggesting disturbances in coagulative processes. The underlying 
defect in the syndrome is, however, considered to be impaired control over function of 
the complement system. This thesis elaborates on the theme of complement regulation 
and discusses defective complement control specifically in the context of aHUS. 
The literature review below first briefly introduces the complement system in general. 
Then, the focus is directed towards regulation of the system, with special attention on 
the complement protein named factor H. Continuing with the theme of control, 
regulation of the complement system by several members of the coagulation cascade 
is described. Next, the disease aHUS is discussed mainly in terms of genetic 
abnormalities of both the complement and coagulation proteins. Finally, a concluding 
overview is presented to illustrate how mutations affect complement cascade function 
and how complement dysregulation is intervowen in aHUS pathogenesis. 
 
2.1 ACTIVATION OF THE COMPLEMENT SYSTEM  
The complement system of serum has traditionally been viewed as a defense against 
foreign intruders [1]. Microbial surface structures initiate the system, and 
amplification and propagation of complement leads to tagging of pathogens for 
destruction. Immune complexes, cellular debris, and altered host cells also activate 
complement, and tactful control of the attack ensures silent clearance of, for example, 
apoptotic cells. Today we know that there is much more to complement function than 
just participation in elimination of microbes or unwanted host material. Namely, 
complement is also involved in such diverse processes as synaptic pruning and 
neuroprotection [2], lipid metabolism [3], mobilization and homing of hematopoietic 
stem-progenitor cells [4], and bone development and homeostasis [5]. 
The complement system is a hub-like network composed of over 30 different proteins 
that either circulate the body in plasma or reside on cell membranes [1]. The default 
state of complement is inactive, but an encounter with a suitable target sets this system 
in motion. Activation of an initiating zymogen triggers a cascade of proteolytic 
cleavages, and zymogens further downstream become activated in a specific sequence. 
If left uncontrolled, the self-amplifying nature of the complement leads to deposition 
of certain protein fragments on target surfaces and to liberation of others into the fluid 
nearby. It is these cleavage products that are responsible for the effector functions of 
the complement system. 
2.1.1 PATHWAYS OF COMPLEMENT ACTIVATION 
The complement system can be initiated by three distinct ways – the classical, the 
lectin, and the alternative pathway – which share a common terminal pathway (Fig. 2).  
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Figure 2. Complement pathways. The 
complement system can be initiated by the 
classical, lectin, and alternative pathways. 
All these converge to a common terminal 
pathway. 
 
 
 
 
 
Function of the different complement pathways is fairly complex (Figs. 3 and 4) [1, 6].  
The classical pathway is triggered by structural surface patterns and certain types of 
immunoglobulins. These are recognized by C1q, and thereby attract the C1 complex 
(C1qr2s2) onto activator surfaces. Surface recognition by C1q is believed to cause a 
conformational change in C1q, leading to auto-activation of C1r, which then cleaves 
C1s. Subsequently, C1s interacts with C4, resulting in surface deposition of C4b in the 
immediate vicinity of the bound C1 complex. C1s also cleaves C2, thus leading to 
formation of the classical pathway C3 convertase C4bC2a. This enzyme complex uses 
C3 molecules as its substrate, producing C3a and C3b. The C3b fragment can either 
become covalently attached to the surface nearby or be liberated to the fluid along with 
the anaphylatoxin C3a. 
Also the lectin pathway results in deposition of C4bC2a convertases on target surfaces, 
but the pattern-recognition molecules triggering activation and the proteases involved 
are different. Namely, the lectin pathway is initiated by binding of mannose-binding 
lectin (MBL) or ficolins to certain carbohydrate structures on target surfaces, resulting 
in activation of MASPs (MBL-associated serine proteases) and thereafter cleavage of 
C4 and C2. 
Unlike the classical and lectin pathways, alternative pathway activation does not 
necessitate surface recognition. Instead, it is believed that a slow tick-over hydrolysis 
reaction producing an active form of C3 (called C3H2O) is involved. C3H2O binds factor 
B, and a proteolytic activation by factor D produces the fluid phase C3 convertase 
C3H2OBb. This enzyme cleaves C3 molecules, and some of the resulting C3b becomes 
covalently attached to the surface nearby. Surface-bound C3b can then form the major 
alternative pathway C3 convertase (C3bBb). This applies also to C3b originating from 
classical and lectin pathway activation, and thus the alternative pathway functions as 
an amplification step for the other two activation pathways.  
When the density of C3b on a target surface increases, the deposited C3b somehow 
changes the substrate specificities of C4bC2a and C3bBb, and cleavage of C5 begins. 
This marks the initiation of the common terminal pathway of complement. Similar to C3 
cleavage, C5 cleavage results in formation of a small chemotactic and anaphylatoxic 
fragment (C5a) and a larger entity called C5b. Unlike C3b, C5b is not covalently 
attached to target surfaces, but instead associates first with C6. When C7 joins the 
complex, insertion to cell membrane occurs. Further interactions of C5b-7 with C8 and 
several units of C9 result in formation of a lytic membrane pore (C5b-9, also known as 
the membrane-attack complex or MAC). 
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Figure 3. Complement activation pathways. The complement system can be initiated by three 
distinct pathways: the classical, the lectin and the alternative pathway. These converge to a 
common terminal pathway. See main text for a more detailed description of the molecular events 
involved. 
 
 
2.2 REGULATORY PROTEINS OF THE 
COMPLEMENT SYSTEM 
The spontaneous tick-over of C3 predisposes all host surfaces in contact with plasma 
to a constant threat of a complement attack. The covalent attachment of C3b to target 
surfaces necessitates only the presence of either –OH or –NH2 groups on them, a 
criterium that is fulfilled by all biological surfaces [7]. Considering the amplifying 
nature of the alternative pathway [8], it is evident that uninhibited propagation of the 
complement cascade quickly leads to massive release of physiologically active 
products and thereby damage to host tissues. On the other hand, moderate formation 
of complement activation products is necessary for many biological processes to occur. 
Thus, to allow initiation and amplification of the complement cascade to some extent, 
but at the same time prevent complement propagation from running completely out of 
control, the system needs to be tightly regulated. To this end, an army of versatile 
regulators has evolved (Fig. 4).  
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Figure 4. The complement system is controlled by an army of regulators. The complement cascade 
is presented with an arrow chart (black). Regulators are placed in the chart close to the steps on 
which they exert their function. Inhibitors are highlighted in red and the only enhancer (properdin) 
in green. Descriptions of regulator functions are presented in grey. See main text for further 
explanations. 
 
 
2.2.1 MEMBRANE COMPLEMENT REGULATORS 
Most cells of the body express membrane-bound complement regulators on their 
surfaces [9]. These inhibitors act on different steps of the complement cascade, and 
together help in adjusting the severity and the extent to which the cascade is allowed 
to proceed. 
Decay-accelerating factor (DAF) is a glycosylphosphatidylinositol-anchored membrane 
glycoprotein that is present on most cells [10]. DAF exerts its regulatory function on 
the complement system by accelerating the decay of C3 convertases. In other words, it 
enhances dissociation of C2a from C4bC2a and Bb from C3bBb, thus preventing further 
C3 cleavage.   
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Membrane cofactor protein (MCP), on the other hand, performs its function by assisting 
in inactivation of surface-bound C4b and C3b [11]. MCP binds both of these deposition 
fragments, and thereafter attracts factor I from the fluid phase to execute the 
proteolytic cleavages. C3b is cleaved at two sites to form iC3b, which can no longer bind 
factor B or support further complement activation. The product iC3b is not, however, 
without function. It serves, for example, as a recognition molecule for receptors on 
macrophages in guiding them to phagocytose apoptotic cells. Similar to DAF, MCP is 
widely distributed on most cells, with the notable exception of erythrocytes. 
The complement receptor 1 (CR1) shows both decay-accelerating and cofactor activities 
[12]. Unlike MCP, CR1 is capable of assisting FI also in the further cleavage of iC3b, 
which leaves only the small C3dg part on cell surface and liberates C3c into the fluid 
phase.  
CD59 (or protectin) is the regulator responsible for limiting complement activity that 
has proceeded to the terminal phase [13]. CD59 binds C8 and C9 and inhibits 
polymerization of C9, thereby preventing formation of the lytic C5b-9 complexes in 
membranes. 
Proper control of complement activation on cell surfaces is critically important. The 
down-regulation of membrane-bound complement inhibitors that occurs in apoptosis 
[14] is presumably related to the role of complement activation in removal of dying 
cells. Complete absence of membrane regulators, however, has deleterious effects. 
Patients with paroxysmal nocturnal hemoglobinuria, for example, lack both DAF and 
CD59 on their blood cells, leading to complement-mediated hemolysis and other 
manifestations of the disease [15]. The cell-based complement regulators are not, 
however, sufficient to protect host tissues from complement attack. The necessary 
additional control is exerted by fluid phase complement regulators, as described in the 
following. 
2.2.2 COMPLEMENT REGULATORS IN PLASMA 
The soluble complement regulators circulate the body in plasma, and are attracted 
onto self cells when additional control of the complement cascade is needed on their 
surfaces.  
C1 inhibitor (C1-INH) is a classical pathway regulator that hampers function of activated 
C1 complexes [16]. C1-INH works by acting as a substrate for the proteases C1r and 
C1s of the C1 complex. In the process, two C1-INH molecules become stably attached 
to C1r and C1s, and the C1 complex is forced to dissociate.  
MAP-1 and sMAP are complement regulators that specifically inhibit initiation of the 
lectin pathway [17]. These proteins are products of alternatively spliced MASP genes, 
and lack the serine protease domains necessary for complement activation. Thus MAP-
1 and sMAP function as competitive inhibitors of the actual MASP proteases in binding 
to MBL. 
C4b-binding protein (C4BP) inhibits the function of C4b in several ways [18]. For 
example, C4BP accelerates the natural decay of C4b-containing convertases. C4BP can 
also prevent formation of new C4bC2a complexes by competing with C2 in binding to 
C4b. Further, C4BP serves as a cofactor for FI in proteolytic inactivation of C4b. 
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Factor H (FH) is the main regulator of the alternative pathway of complement. It 
displays functions similar to C4BP, but instead of C4b, FH works on C3b and C3bBb. FH 
is discussed in detail in the following chapter. 
As has been disclosed above, the regulators displaying cofactor activity (MCP, CR1, 
C4BP, and FH) only assist in degradation of the activation fragments produced during 
propagation of the complement cascade. The protease performing the actual cleavages 
is Factor I (FI). Cofactor involvement is necessary, since FI is incapable of cleaving C4b 
or C3b on its own. The ability of FI to degrade both C4b and C3b makes it an essential 
inhibitor of all activation pathways  [19].  
Vitronectin (or S-protein) is an adhesive glycoprotein, that has been shown to bind C5b-
7, and prevent this complex from further interacting with C8 and C9 [20]. It has been 
reported to benefit bacteria in their battle against the human complement [21], but 
otherwise the role of vitronectin in regulating complement in vivo remains somewhat 
unclear. 
Properdin is the only regulator known to enhance activation of the complement system. 
Original research in 1954 suggested properdin to initiate complement activation 
through the alternative pathway [22], but mistrust in this work caused the scientific 
community to dismiss properdin for years. Then, two decades later, a stabilizing 
function for properdin was confirmed by a study showing that properdin slows down 
the decay of C3bBb by at least 10-fold [23]. Today it is known that the original proposal 
was true after all, with properdin-mediated complement initiation shown on biosensor 
chips, pathogenic bacteria, and altered self cells [24]. However, results of properdin 
studies need to be interpreted with great caution. Namely, unless specifically removed, 
the unphysiological, polymerized protein (that is present in thawed properdin 
samples) leads to erroneous activation of complement against several targets [25].  
2.2.2.1 THE REGULATOR FACTOR H 
The regulatory protein factor H, earlier known as β1H-globulin or C3b inactivator, is 
an abundant plasma protein with a concentration range from 116 to 562 µg/ml [26]. 
The single 155 kDa polypeptide chain of FH carries several glycosylations [27], but 
these are dispensable for its function [28]. FH is composed of 20 consecutively 
arranged globular domains termed CCP (complement control protein) or SCR (short 
consensus repeat) [29], and is therefore generally illustrated as a string of 20 beads 
(Fig. 5). The exact structure of full length FH is as yet unresolved, but early electron 
microscopy studies have suggested an extended, flexible molecule that mostly folds 
back on itself [30]. Later, this proposition of bent back structure has received further 
support from analytical ultracentrifugation and small-angle X-ray scattering studies 
[31, 32], but the flexibility of the molecule has been questioned. Instead, the central 
domains 10-15 of FH have recently been proposed to form a compact, rigid structure 
[33]. The high inter-domain tilt between CCPs 13 and 14 was speculated to function as 
a “hinge” [34], and to allow FH to fold back on itself. 
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Figure 5. Factor H is composed of 20 
consecutively arranged, globular CCP 
domains. FH contains 9 % carbo-
hydrate [27], and shown are the 
domains predicted to bear N-linked 
glycosylations [31]. 
 
 
 
FH displays several complement inhibitory functions [35]. First, FH acts as a 
competitive inhibitor of factor B in binding to C3b, and thereby prevents formation of 
C3bBb complexes. Second, FH guides FI to bind C3b, and assists FI as a cofactor in 
cleavage of C3b to the inactive iC3b. Third, FH accelerates dissociation of Bb from the 
alternative pathway convertase C3bBb. All these functions are dependent on a few 
domains in the N-terminus of FH [36-39], and the crystal structure of C3b in complex 
with FH domains 1-4 illustrates how (Fig. 6) [40]. The decay-accelerating activity can 
be explained by electrostatic repulsion and steric clash between the negatively charged 
domains 1 and 2 of FH and Bb, which lead to displacement of Bb from the C3bBb 
complex. The role of FH as a cofactor in C3b degradation, on the other hand, 
necessitates participation of the third domain of FH as well, and together CCPs 1-3 of 
FH provide a platform for FI to bind. The structure of the complex between C3b and the 
N-terminus of FH has later been validated with solution-based fluorescence resonance 
energy transfer analyzes [41].   
In addition to the N-terminal CCPs, the centrally located FH domains 12-14 have been 
proposed to interact with C3b [42]. Later investigations were not able to confirm 
binding of FH domains 12-14 (or even domains 10-15) to C3b, thus questioning the 
existence of the site altogether [43]. It remains possible, however, that the central part 
of FH bears low affinity for C3b, but that this becomes evident only in the form of 
increased C3b-binding avidity of another site on FH [44]. One should also note, that the 
central part of the human factor H molecule is heavily glycosylated with specific 
oligosaccharides [31], but the FH fragments used in the above mentioned studies were 
produced either in baculoviral [42] or yeast [43] expression systems incapable of 
equipping protein fragments with correct glycans. Even though the glycosylations are 
not necessary for FH function [28], they bring negative charge to several of the domains 
[32], and could therefore affect FH interactions with C3b. Thus, if the search for a C3b-
binding site in the middle part of FH is continued, this should be done using FH 
fragments expressed in a mammalian production system.  
Similar to the N-terminus of FH, the C-terminal part of the molecule shows reasonable 
affinity for C3b, with a dissociation constant of 0.54 µM measured for the interaction 
[45]. Co-crystals between FH domains 19-20 and the C3d-part of C3b have revealed 
several binding interfaces between these molecules [45, 46], but mutagenesis and NMR 
data suggest that only one of these (Fig. 6) has physiological relevance [46]. Binding of 
FH domains 19-20 to C3b is imperative for proper control of complement on surfaces 
[47, 48], but, by no means sufficient. If it was, then FH would prevent complement 
propagation on all surfaces alike, including bacteria. Instead, careful target 
discrimination by FH is observed, resulting in inhibition of complement activity only 
on certain surfaces. The common feature of these non-complement-activators is 
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expression of specific molecular structures (self markers) that are recognized by the 
C-terminus of FH. The presence of these interaction partners on cells increases FH 
binding to cell-deposited C3b roughly 10-fold [49], underlining the importance of 
domains 19-20 in FH function. Several biomolecules have been suggested to be 
responsible for the enhanced FH interactions – most notably sialic acid [50] and 
glycosaminoglycans [51] – but the identity of the FH binding structure on different 
human cells remains unconfirmed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Interactions of FH fragments (blue) with C3 fragments (green). Left: Binding of the 
N-terminal domains 1-4 of FH to C3b. Right: Binding of the C-terminal domains 19-20 of FH 
to the C3d-part of C3b. Pictures were drawn with the PyMol software using Protein Data 
Bank files (ID codes 2WII and 2XQW) as the input data [40, 45]. 
 
 
 
 
2.3 SURFACE STRUCTURES AND COMPLEMENT 
REGULATION 
The extent of complement propagation on self cells depends not only on expression of 
specific regulatory complement proteins, but also on the molecular features of the cell 
surfaces themselves. Whereas antigenic cell epitopes and certain carbohydrates are 
capable of initiating complement activation, other surface structures attract backup 
forces from plasma to prevent the complement attack from becoming too excessive. 
Sialic acids, glycosaminoglycans, and malondialdehyde adducts are examples of 
surface structures that have been proposed to guide FH onto self cells. 
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2.3.1 SIALIC ACIDS 
Sialic acids are a class of sugars containing a nine-carbon backbone (Fig. 7). They are 
found mainly at terminating branches of oligosaccharides on glycoproteins and 
glycolipids, and thus decorate surfaces of all vertebrate cells [52-54]. The 
concentration of sialic acid in the cell surface glycocalyx has been estimated to 
approach 100 mM [55]. Sialic acids show remarkable structural diversity [56]. Besides 
the modifications at different backbone carbons, variation stems from the type of 
glycosidic linkage between sialic acid and the underlying glycan and from the structure 
of the oligosaccharide in general.  
Sialic acids contribute to several biological systems [54, 57]. For example, their 
abundance on erythrocyte surfaces results in negative charge repulsions that prevent 
inappropriate cell interactions with the surroundings. Further, sialic acids act as 
ligands for cell adhesion molecules, and participate in, for example, leukocyte rolling. 
Moreover, sialic acids protect cells from complement activation. 
 
 
 
 
Figure 7. The most common sialic acid found on mammalian 
cells is the N-acetylneuraminic acid (Neu5Ac). This 
monosaccharide carries a negative charge in its carboxylate 
group at position C1 and forms -linkages with underlying 
glycan structures through the oxygen in C2.  Carbons C7, 
C8, and C9 with their hydroxyl groups constitute a glycerol 
side chain important for Neu5Ac interactions with FH.[58] 
 
 
 
 
2.3.1.1 THE PROTECTIVE EFFECT OF SIALIC ACID 
The role of sialic acid in complement regulation in general has been investigated since 
the 1960’s [59]. Early experiments involved mainly erythrocytes, but liposomes and 
bacteria soon followed in the wake. The major problem with many studies was that 
even though they mostly showed increasing complement activation with decreasing 
surface sialic acid, they did not allow distinguishing between different mechanisms by 
which sialic acid exerts its protective effect.  
Removal of sialic acid from human cell surfaces exposes the underlying glycan 
structures, which are mainly galactose residues [53]. These are recognized by both 
natural antibodies [60, 61] and the pattern recognition molecule C1q [62], and 
initiation of the classical pathway of complement follows. Thus, the observed 
enhancement of complement activity due to sialic acid removal [63, 64] can be 
explained as to result from complement initiation through the classical pathway. The 
experiments do not, however, reveal whether other mechanisms besides galactose 
masking are involved in sialic acid-mediated protection from complement. 
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But how to circumvent the problem of natural antibodies? The traditional solution 
would be to perform the assays in a buffer containing EGTA, which allows complement 
activation only through the alternative pathway [65, 66]. However, although EGTA 
halts complement initiation through the classical and lectin pathways, antibodies can 
activate the complement system also through the alternative pathway [67-69]. Thus, 
even in the presence of EGTA, the role of natural antibodies in enhancing complement 
activation on sialic acid-deficient cells [50, 64, 70] cannot be excluded. A second 
solution is to replace cells with liposomes, which are devoid of antigenic epitopes. With 
glycolipids GM1 and GM3, and the protein glycophorin A it has indeed been shown that 
sialic acid hinders complement activation in serum, and presumably does this by 
controlling the alternative pathway of the cascade [71-73]. A third approach to the 
problem is to add free galactose to serum, but it is questionable, whether this 
monosaccharide could efficiently compete with the galactose-containing epitopes on 
sialidase-treated surfaces for binding to natural antibodies. In contrast to this, the 
fourth solution of complete removal of immunoglobulins from the system should solve 
the problem effectively [67], but no data on complement activity on sialidase-treated 
mammalian cells in agammaglobulinemic serum can be found. 
Similar to mammalian cells, many experiments with bacteria show decreasing 
complement activation with increasing surface sialic acid [59, 74-78] but provide no 
insight into the actual mechanism with which sialic acid protects surfaces from 
complement. However, showing sialic acid-mediated protection using preabsorbed 
serum [79] and EGTA-inhibited immunoglobulin-deficient serum [67, 80] indicated 
that sialic acid regulates the alternative pathway of complement. 
 
 
 
2.3.1.2 SIALIC ACID AND FACTOR H FUNCTION ON SURFACES 
In parallel with research on the role of sialic acid in complement regulation in general, 
the significance of sialic acid for FH function in particular has been investigated. 
The affinity of FH for sialic acid is very low. Binding has been observed only in a buffer 
with 1/10 physiological ionic strength [81], and the dissociation coefficient of the 
interaction was recently estimated to lie in the µM or mM range [58]. Even though too 
weak on its own, sialic acid in combination with surface-deposited C3b can remarkably 
enhance FH binding. Introduction of the sialoglycolipid GM1 to C3b-bearing liposomes 
doubled FH binding [73], and erythrocyte assays revealed sialic acid to enhance FH 
affinity to them 10-fold [49, 82]. Importantly, sialic acid not only enhances FH binding 
to surface-deposited C3b, but also boosts FH regulatory function, as shown by the 
acceleration of FH-mediated C3bBb decay on sialic acid bearing surfaces [50]. 
An explanation for the enhancing effect of sialic acid on FH function was recently 
provided by a structural study. In this work, the C-terminus of FH responsible for 
binding sialic acid [83] was crystallized with both a sialic acid-containing trisaccharide 
3’sialyl lactose and the C3d-part of C3b [58]. The ternary structure showed that two 
non-overlapping sites in FH domains 19-20 interact simultaneously with sialic acid and 
C3d (Fig. 8). Thus, even though too weak on their own, FH-interactions with sialic acid 
presumably contribute to the avidity of FH for C3b. 
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Figure 8. FH domains 19-20 
(blue) interact with sialic acid. 
Left: The residues predicted to be 
important for FH interactions with 
sialic acid [58] are highlighted in 
yellow. Right: Simultaneous 
binding of FH to sialic acid-
containing trisaccharide 3’sialyl 
lactose (red) and the C3d-part of 
C3b (green) [58]. Pictures were 
drawn with the PyMol software 
using a Protein Data Bank file (ID 
code 4ONT) as the input data 
[58]. 
 
 
 
 
The recent structural data on FH interactions with sialic acid allow us to better explain 
the results of some earlier studies. For example, the ternary complex shows the 
importance of the glycerol side chain of sialic acid for the interaction [58]. This chain 
inserts into a mainly hydrophobic pocket in FH domain 20, and the 9-OH group of the 
chain forms hydrogen bonds with residues in FH. Thus, increased complement 
activation observed on removal of 9-O-hydroxyl groups from liposome surface sialic 
acid [84] is presumably due to deletion of the necessary bonds between the 9-OH of 
sialic acid and FH. On the other hand, acetylation of the 9-OH group prevents insertion 
of the glycerol side chain into its pocket in FH, and binding of acetylated sialic acid to 
FH cannot occur. This explains the positive correlation between complement activation 
and degree of sialic acid 9-O-acetylation on various human and murine cells [85-89]. 
Further, the co-crystal structure suggests that formation of the ternary complex 
between FH, sialic acid, and C3b is important for FH function [58]. In other words, 
mutations impairing FH interactions with either sialic acid or C3b should impede FH 
function by preventing proper formation of the complex. And indeed, even though 
some mutations in FH domains 19-20 decrease and others increase the affinity of 
FH19-20 for C3b, all 16 mutations have an identical effect on FH function: they hamper 
FH regulation on sialic acid-bearing erythrocytes [90]. Taken together, experimental 
data is strongly in favor of sialic acid to be critical for FH function on erythrocytes.  
 
2.3.1.3 SIALIC ACIDS AS COMPLEMENT ACTIVATION ENHANCERS 
Sialic acids have also been proposed to enhance complement activation. According to 
one model [91], sialic acids of glycophorin provide newly formed C5b6 complexes a 
means to adhere to cell surfaces. Due to the weakness of this interaction, C7 can easily 
escort the loosely bound C5b6 further closer to the cell membrane. Supporting the 
model, anti-glycophorin antibody fragments were shown to inhibit hemolysis [91]. 
Further, insertion of sialoglycolipids into erythrocyte membranes was observed to 
increase hemolysis [91, 92], whereas removal of sialic acid decreased cell lysis [93]. 
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Some challenges for the model, however, remain. First, the interaction between C5b6 
and glycophorin is so weak, that it is questionable whether it can be of physiological 
significance. Namely, the C5b6 complex elutes from a glycophorin column at an ionic 
concentration corresponding to only 30 % isotonic buffer [91]. On the other hand, too 
high affinity of C5b6 for a membrane component prevents C5b-7 insertion into 
membrane [94], although the contrary has also been reported [95]. Second, plasma 
proteins in general contain glycans that terminate in sialic acid. It has been shown that 
fluid phase glycophorin impairs C7-mediated insertion of C5b6 into cell membrane  
[96]. It is expected that the sialylated plasma proteins would similarly compete with 
cell membrane glycophorin for binding to C5b6, and prevent further interactions with 
cell membrane. All in all, further research is required to confirm the role of sialic acid 
in terminal pathway regulation. 
Besides hiding underlying galactose epitopes from natural antibodies, sialic acids have 
also been reported to act as antigens themselves. The ends of human oligosaccharides 
generally terminate with the sialic acid Neu5Ac (Fig. 9), which performs a protective 
masking function and is not antigenic. However, consumption of red meat and dairy 
products leads to incorporation of Neu5Gc (Fig. 9) in cell membranes [97] in place of 
Neu5Ac. Humans are unable to synthesize Neu5Gc, and this sialic acid is recognized as 
foreign, leading to generation of anti-Neu5Gc antibodies [98]. The simultaneous 
presence of Neu5Gc on cells and anti-Neu5Gc antibodies in plasma has been proposed 
to, for example, spur inflammation and mediate development of cancer (reviewed in 
[57, 99, 100]). 
 
 
 
 
Figure 9. The sialic acid N-glycolylneuraminic acid 
(Neu5Gc). Neu5Gc differs from the most common 
human sialic acid (Neu5Ac) by only one hydroxyl 
group (highlighted with a dotted ellipse).  
 
 
 
 
 
2.3.2 GLYCOSAMINOGLYCANS 
The second family of cell surface components associated with complement regulation 
are glycosaminoglycans (GAGs). GAGs are linear, 10-100 kDa polymeric chains 
covalently attached to core proteins [101]. These complex carbohydrate structures 
show wide structural diversity with the variation stemming from, for example, the 
repeating disaccharide units forming the chains and from the patterns of sulfation. 
GAGs form a major constituent of the cell surface glycocalyx [102]. Heparan sulfate 
(Fig. 10), the major GAG in mammalian cell glycocalyx, plays an essential role in most 
physiological processes [102].  
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Figure 10. Heparan sulfate and heparin are linear chains of repeating disaccharide units. Left: The major 
repeating unit in heparan sulfate does not contain sulfate groups. Right:  Heparin, on the other hand, is 
highly sulfated.[101] 
 
2.3.2.1 HEPARIN AND COMPLEMENT ACTIVATION IN GENERAL 
Although glycosaminoglycans are mainly found as covalently attached to cell surface 
proteins, most complement-related research on GAGs has been performed with fluid 
phase glycans. The best studied GAG is probably heparin, which resembles heparan 
sulfate but displays a higher degree of sulfation (Fig. 10) [101].  
The first report of heparin to regulate complement activation was published in 1929 
(Ecker and Gross, J. Infect. Dis.). Subsequent research has mainly supported the 
original observation [103-114], and experiments with guinea pigs have shown heparin 
to hinder complement propagation also in vivo [115]. Very low concentrations of 
heparin, however, have somewhat surprisingly also been claimed to enhance 
complement activation [116, 117]. 
One of the steps at which heparin exerts its complement regulatory effect is the 
proteolysis by the classical pathway protease C1. Heparin potentiates the inactivating 
function of C1-INH on C1 [118-120] by increasing the reaction rate 35-fold [121]. 
Proper enhancement of C1-INH function seems to necessitate formation of a ternary 
complex between heparin, C1-INH, and C1 [122]. Further, heparin has also been 
claimed to regulate the antithrombin-mediated inhibition of MASPs 1 and 2 [123, 124]. 
Besides C1-INH, heparin has also been reported to interact with over 10 other proteins 
of the complement system (Table 1) [125, 126]. Mere binding to heparin does not, 
however, prove that some GAG would be involved in function of all these proteins in 
vivo. Namely, self cell membranes are mostly decorated with heparan sulfate [127], not 
heparin, and these two glycosaminoglycans differ markedly at molecular level (Fig. 
10). Thus, no conclusion on complement protein function on heparan sulfate-covered 
cell surfaces can be drawn on the basis of binding of these proteins to heparin. Related 
to this, in one study, removal of heparan sulfate from human kidney cells was claimed 
to inhibit complement activation by decreasing properdin binding [128]. However, the 
authors had not separated the polymerized properdin from the natural multimers 
[128] as should have been done [25], and thus the observed complement activity was 
probably due to erroneous complement cascade initiation by denatured properdin.  
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Table 1. Complement proteins reported to interact with heparin. Note that Sahu et al. [126] 
also experimented with C3, C5, C7 and factor I, but in contrast to Yu et al. [125], observed no 
binding to heparin. 
Reference Complement proteins showing heparin binding 
Sahu et al. (1993) C1q, C2, C4, C6, C8, C9, C1-INH, C4BP, factor B,  
factor D, factor H, properdin, vitronectin 
Yu et al. (2005) C1, C2, C3, C4, C5, C6, C7, C8, C9, C1-INH, 
factor I, factor H, factor B, properdin 
 
2.3.2.2 INTERACTIONS OF FACTOR H WITH HEPARIN  
The origin of research on FH interactions with heparin dates back to the 1970’s. It was 
reasoned that because mammalian serum fails to lyse homologous cells, protective 
elements necessarily exist on cells [129]. Heparin was considered a suitable candidate, 
since the presence of the similar heparan sulfate on various cells had newly been 
discovered and since purified heparin happened to be available for the authors. Thus, 
heparin was coupled to yeast particles and studied for its complement inhibitory 
potential. And indeed, the covalently attached heparin was observed to enhance FH-
mediated complement regulation on the particles. Although never properly 
investigated with cells, the following years witnessed general acceptance of GAGs to be 
responsible for directing FH onto, for example, endothelial cells to limit complement 
propagation on them. 
Over the years, several sites on FH have been proposed to mediate binding of this 
regulator to heparin. The binding site was originally delimited to domains 12-15 using 
tryptic cleavage fragments and photoaffinity labeling [130]. The site was further 
restricted to domain 13 due to the high content of suitably spaced lysines in this 
module. Later studies with recombinant fragments, however, proved domain 13 to be 
dispensable for FH interactions with heparin. Instead, an important role in the binding 
was assigned for domain 7 [131]. An additional heparin-binding site was also predicted 
to lie in FH domains 10-20 [131], and soon after, domain 20 was verified as the second 
heparin interaction site of FH [132].  Then, domain 9 was proposed to also contribute 
to FH interactions with heparin [133]. However, these claims were based on studies 
performed with recombinant FH fragments containing additional artifact arginine 
residues. These were later confirmed to have falsified the binding properties of the FH 
fragments, and to be responsible for the erroneous interpretation of FH domain 9 to be 
involved in FH interactions with heparin [43]. Thus, the true binding sites for heparin 
on FH reside in domains 7 and 20 (Fig. 11). 
 
 
 
 
 
Figure 11. Factor H binds heparin with sites located in domains 7 and 20. 
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Several attempts have been made to define the heparin binding residues in FH in more 
detail. In the case of domain 7, molecular modelling initially revealed a patch on module 
7, which contained several basic residues considered important for interactions with 
heparin [134]. These predictions were not supported by a later study, where the FH 
fragment 6-8 was co-crystallized with a short heparin analogue [135]. Rather, residues 
at several distinct sites along the length of the FH fragment 6-8 were observed to 
interact with the glycan. Experiments with NMR supported the X-ray results. This led 
the authors to propose that, instead of a site restricted to one module, an elongated 
binding area exists on FH and extends from domain 7 onto the neighboring modules 6 
and 8.  
In contrast to FH domains 6-8, the fragment 19-20 has resisted co-crystallization with 
oligosaccharides, and therefore several other methods have been employed instead. 
Homology modelling, for example, predicted four arginine or lysine residues in FH 
domain 20 to mediate interactions with heparin (Fig. 12, left) [136]. Later, heparin 
binding of three of these residues was asserted by an NMR study, which showed a total 
of 15 residues in domain 20 to interact with a sulfated tetrasaccharide (Fig. 12, middle) 
[137]. The data obtained with NMR, in turn, compared reasonably well with the results 
of mutational studies (Fig. 12, right) [90, 138, 139]. In these experiments a site map 
was generated by comparing binding of wt FH19-20 to FH19-20 fragments containing 
a mutation associated with the disease aHUS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Factor H domain 20 harbors a binding site for heparin. Various methods have 
been used to elucidate the residues involved in the interaction. The predictions based on 
homologous modelling (left), NMR (middle) and mutagenesis (right) show substantial 
overlap.  
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2.3.2.3 GLYCOSAMINOGLYCANS AND FACTOR H FUNCTION 
Whereas most research on FH interactions with GAGs seems to have concentrated on 
heparin, the major GAG present on cell surfaces is heparan sulfate [102]. Thus, FH 
interactions with this GAG are of greater interest, and some data on the issue is already 
available. For example, binding of full length factor H to renal proximal tubular 
epithelial cells was observed to decrease after removal of heparan sulfate from cell 
surfaces [140]. Similarly, heparinase pretreatment of human eye tissue significantly 
reduced binding of anti-FH antibody [141]. Binding to cell surface heparan sulfate has 
been shown for both heparin-binding domains of FH: heparan sulfate attracts domains 
6-8 onto structures of the eye macula [142] and domains 19-20 onto the kidney 
glomeruli [51]. However, sheer binding of FH to heparan sulfate on cells does not 
necessarily translate into enhanced FH function on heparan sulfate-bearing surfaces. 
Whereas coating yeast particles with heparin has been shown to potentiate FH function 
on their surfaces [129], it remains to be studied, whether the same is true of heparan 
sulfate on cells.    
2.3.3 MALONDIALDEHYDE ADDUCTS  
The newcomer among cell surface candidates for the FH binding partner is a group of 
structures called malondialdehyde (MDA) adducts [143]. MDA is an aldehydic lipid 
degradation product with potential to modify cellular components [144]. In basic 
solutions, MDA exists predominantly in the less reactive enolate form, whereas at 
lower pH, the prevailing species is the more reactive β-hydroxyacrolein (Fig. 13).  The 
latter form reacts with primary amino groups on proteins and lipids, leading to 
formation of various covalent structures (Fig. 13).    
In vivo, some MDA is liberated enzymatically by thromboxane synthetase in the course 
of platelet activation [145]. The main source of MDA, however, is non-enzymatic 
degradation of polyunsaturated lipids, which follows from lipids being attacked by 
reactive oxygen species during oxidative stress [144, 146]. As for oxidative stress, this 
imbalance has been associated with most known diseases, although a causative link 
has been proven only for a few pathological conditions [147].  
In biological samples, the presence of MDA adducts is generally shown 
immunologically. Anti-MDA-epitope antibodies have been demonstrated to recognize 
antigenic material, for example, in the retinal deposit lipofuscin [148], on apoptotic 
porcine cells [149], in atherosclerotic lesions [143, 150], and the low density 
lipoproteins extracted from them [151]. Instead of antibodies, with in vitro MDA-
modified proteins the method commonly adopted for analyzing the concentration of 
MDA adducts is the trinitrobenzenesulfonic acid test of Habeeb [152]. Rather than MDA 
adducts, this method determines the percentage of lysine residues of a protein that 
have become modified during MDA treatment. Further, MDA modifications have also 
been analyze by employing fluorescence measurement techniques [153]. Namely, 
especially in the presence of acetaldehyde, MDA modification of proteins leads to 
formation of the fluorescent heteroaromatic adducts named 4-methyl-1,4-
dihydropyridine-3,5-dicarbaldehyde (MDHDC) (Fig. 13) [154, 155]. Understandably, 
specific fluorescence of a modified sample demonstrates only the presence of MDHDC 
adducts, but conveys no information on the more simple MDA-adduct structures.   
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Figure 13. Structures of malondialdehyde (MDA) 
and various adducts formed upon MDA modification.  
(A) MDA exists mainly in the trans-isomeric enolate 
form in water (above), but it is the β-
hydroxyacrolein form (below) that is the more 
reactive one. (B-E) Reactions of MDA with primary 
amino groups of lysines lead to formation of various 
adducts. Shown are schematic structures for 
adducts (B) 2-formyl-3-(alkylamino)butanal [156], 
(C) N-2-propenal [157], (D) 1-amino-3-imino-
propene [144], and (E) 4-methyl-1,4-dihydro-
pyridine-3,5-dicarbaldehyde (MDHDC) [154, 155].  
 
 
 
2.3.3.1 INTERACTIONS OF MDA-MODIFIED PROTEINS WITH FACTOR H 
The interaction between MDA adducts and FH was reported only quite recently [143]. 
Very few publications have touched upon the subject thereafter, and thus our 
knowledge especially on the significance of the interaction remains very limited. The 
original work demonstrated that binding of FH to MDA-modified BSA is mediated by 
the same FH domains that are responsible for FH interactions with heparin, i.e. 
domains 6-8 and 19-20 [143]. The relative contribution of each site for binding of the 
full length FH to MDA-modified BSA could not be deduced from the reported data. 
Subsequently, a mini-FH, which contained FH domains 1-4 linked to domains 19-20, 
was observed to display 75 % less binding to MDA-modified BSA when compared to 
full length FH [158]. This suggested domains 6-8 to be more important for the 
interaction. However, the mini-FH contained a C-terminal His-tag [159] which might 
have artificially impaired the binding properties of the construct. Furthermore, proper 
binding of FH to MDA-modified targets might necessitate both FH sites to be 
simultaneously present. Domains 6-8 alone might display equally poor binding to 
MDA-BSA as was reported for 19-20 alone [159]. 
In the article that first described FH binding to MDA adducts, it was claimed that MDA 
adducts recruit FH to surfaces to halt complement activation [143]. However, the 
experiments described in the article only show that FH binds MDA-modified proteins. 
None of the assays prove that MDA adducts would bring about FH-mediated protection 
from complement attack to surfaces bearing these adducts. 
2.3.3.2 THE PROINFLAMMATORY EFFECT OF MDA ADDUCTS 
MDA adducts are an example of the so-called oxidation specific epitopes (OSEs) that 
are generated in increasing amounts in various pathological situations [160]. OSEs are 
recognized by receptors of the innate immune system, with proinflammatory 
consequences. Using retinal pigment epithelial cells and monocytes it has been shown 
that recognition of MDA adducts by cells induces expression of several key genes 
involved in inflammation, such as those of IL-8, TNF-α, and IL-1 [143, 161]. Cell 
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recognition of MDA adducts is probably mediated by scavenger receptor A [162, 163]. 
FH was shown to be capable of inhibiting MDA-BSA-induced IL-8 expression in cells 
[143].  Therefore it was suggested that, in addition to leading to enhanced complement 
regulation on surfaces, FH binding to MDA adducts could be important in neutralizing 
the proinflammatory effects of MDA epitopes. 
MDA adducts are also recognized by some natural antibodies of plasma [164-174]. 
There is, however, considerable uncertainty about the (clinical) significance of these 
antibodies [175]. First, it has been suggested that anti-MDA adduct antibodies (or anti-
OSE antibodies in general) would be important for hiding adducts from their cellular 
receptors, thereby preventing inflammatory responses due to adduct recognition by, 
for example, scavenger receptor A [164]. Second, it has also been proposed that natural 
antibodies would promote clearance of unwanted material (like apoptotic cells) by 
mechanisms involving complement [160]. The literature data on the capability of OSEs 
to activate complement in human serum is not very convincing [176, 177], but IgM 
antibodies against MDA adducts have nevertheless been shown capable of enhancing 
phagocytosis of apoptotic cells [178]. In any case, it remains to be studied what is the 
significance of FH interactions with MDA adducts on complement activation on 
surfaces bearing these OSEs. 
 
 
2.3.4 SUMMARY OF FH BINDING PARTNERS  
As a summary, the important complement regulator FH has been shown to interact 
with several molecular structures, including the GAG heparin, the carbohydrate sialic 
acid, and MDA adducts. The sites of FH involved in binding to these structures are all 
located at or close to FH domains 7 and 20 (Fig. 14). It is stressed that even though 
heparin, sialic acid, and MDA adducts are found in vivo, it is unknown whether these 
structures are truly involved in FH-mediated regulation of complement on self 
surfaces.   
 
 
 
 
Figure 14. Sites involved in interactions of FH with heparin, sialic acid, and MDA adducts 
are located at or near FH domains 7 and 20. Shown are also the C3b-interactions sites 
of FH.   
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2.4 COAGULATION AND FIBRINOLYSIS  
Blood coagulation is a defense mechanism against bleeding. Under normal conditions, 
the anticoagulation state is favored. Injury to endothelial cells, however, exposes tissue 
factor to the bloodstream, setting the coagulation cascade in motion. Ordered series of 
proteolytic activation reactions lead to generation of thrombin, which converts 
fibrinogen to fibrin networks. The coagulation cascade is greatly accelerated on 
surfaces of activated platelets, which adhere to the damaged endothelium and form 
aggregates. A hemostatic plug results at the site of injury. Finally, the clot is resolved 
by the dissolving fibrinolytic action of the protease plasmin (Fig. 15). [179, 180] 
 
 
 
2.4.1 THE COMMON EVOLUTIONARY ORIGIN OF THE COMPLEMENT 
AND COAGULATION CASCADES  
Similar to complement, the coagulation system functions as a network of serially 
activated serine proteases. It has been proposed that these infamous “terrible Cs” [182] 
have  arisen from a single ancestral developmental/immunity cascade [183]. Thus, it is 
not surprising, that the complement and coagulation networks share several common 
functional attributes. For example, they are both activated on foreign or altered self 
surfaces. Once initiated, the cascades proceed through amplification and propagation 
phases, all of which are tightly controlled by several regulatory molecules in order to 
avoid unnecessary harm to the host. Further, both complement and coagulation 
systems respond rapidly and their activation is spatiotemporally limited.[184, 185] 
 
 
2.4.2 CROSSTALK BETWEEN COMPLEMENT AND COAGULATION 
The complement and coagulation cascades are distinct proteolytic pathways, but their 
concurrent activation is evident in several pathophysiological situations [185-187]. 
Intriguingly, there is a growing body of evidence of extensive crosstalk between the 
two cascades [184-191]. Here, two different modes of interaction can be identified. On 
the one hand, complement and coagulation affect each other indirectly through, for 
example, various cell processes. On the other hand, specific direct molecular 
interactions between multiple factors of the two cascades have been reported. Below, 
the interplay between complement and coagulation is discussed in more detail. 
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Figure 15. Cascade model of coagulation with fibrinolysis. Initiation of coagulation occurs when 
injury to endothelium exposes tissue factor (TF) to blood (classically referred to as the extrinsic 
pathway of activation). TF forms a complex with the activated form of factor VII (VIIa) present in 
blood. This complex (TF-VIIa) activates factor X. The resulting Xa associates with the cofactor Va to 
form the prothrombinase complex (Xa-Va) on the TF-expressing cells. Prothrombinase converts 
prothrombin to the active fibrinogen-cleaving protease thrombin.  Thrombin also amplifies its own 
generation by activating factor XI and cofactors V and VIII. Similar to coagulation initiated by TF 
exposure, activation of the so-called contact pathway (classically referred to as the intrinsic 
pathway) also leads to formation of Xa-Va and, thereafter, production of thrombin and conversion 
of fibrinogen to fibrin. The contact pathway is initiated on artificial, negatively charged surfaces 
through interactions between the high molecular weight kininogen (HMWK), prekallikrein (PK) and 
factor XII, but its precise role in in vivo coagulation is still debated [181]. Besides producing fibrin, 
thrombin also activates factor XIII. XIIIa stabilizes the clot by creating covalent cross-links in fibrin 
networks.  Finally, plasminogen is activated to the protease plasmin on fibrin fibers, and the 
fibrinolytic activity of plasmin leads to digestion of fibrin.[179, 180] 
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2.4.2.1 INDIRECT INTERACTIONS BETWEEN COMPLEMENT AND 
COAGULATION SYSTEMS 
The reported indirect interactions between the complement and coagulation systems 
mainly follow the same pattern: activation of complement leads to stimulation of the 
coagulation cascade. For example, antibody-induced complement attack on human 
fibroblasts increases TF expression on cell surfaces [192]. The contrary has also been 
described, with thrombin reported to increase DAF expression on endothelial cells in 
dose-dependent manner [193].  
Considering the C3 step of the complement cascade, it has been shown that the 
anaphylatoxin C3a stimulates coagulation by enhancing platelet activation [194]. In 
mice, deficiency of C3 causes impairment of platelet aggregation and prolongs the tail 
cut bleeding time [195]. Here, however, the complement activation product 
responsible for the observed effects need not have been C3a or C3b. The same is true 
of one study performed with baboons [196]: Although compstatin is a known potent 
inhibitor of C3 conversion [197], the compstatin-dependent decrease in E. coli-induced 
coagulopathic response [196] might as well have involved complement components 
downstream of C3. 
Compared to C3, the ability of C5 fragments to induce procoagulant effects on cells is 
perhaps better established. C5a, for example, induces TF expression in endothelial cells 
[198] and neutrophils [199], and the effect is mediated by the C5a receptor C5aR [199, 
200]. In mast cells [201] and macrophages [202], on the other hand, recombinant C5a 
was reported to significantly increase the expression of the pro-coagulant factor 
plasminogen activator inhibitor-1. Blockage of C5a function by anti-C5a antibody 
ameliorates the negative effects of complement on coagulation [203]. 
Experiments with C6-deficient animals suggested that C5b-9 formation also inflicts the 
coagulant properties of cells [204]. Namely, the absence of C6 in rabbits and mice has 
been reported to prolong blood clotting and tail bleeding times, and to markedly 
decrease prothrombin consumption [204, 205]. In contrast to this, no abnormalities 
with C6-deficient human blood could be observed, but the clotting time and 
prothrombin consumption were reported to be at the upper and lower ranges of 
normal values, respectively [206]. In platelets, insertion of C5b-9 in cell membranes 
seems to cause cell activation, leading to, for example, enhanced prothrombinase 
complex activity on platelet surfaces [207, 208]. Assembly of membrane C5b-9 has also 
been reported to result in shedding of membrane particles from endothelial cells [209] 
and platelets [210]. The microvesicles released are enriched with negatively charged 
sites which attract factor Va of the prothrombinase complex. C5b-8 (or C5b-9) have 
been suggested to exert their effects on coagualtion by inducing transbilayer migration 
of membrane phospholipids [211], and by causing transient depolarization of platelet 
membrane potential [212]. Related to this, complement activation on cells has been 
linked to exposure of phosphatidylserine [213]. Furthermore, complement activation 
has been reported to cause activation of TF on thymocytes, and membrane insertion of 
C5b-7 was suggested to be responsible through activating the cell surface protein 
disulfide isomerase [214]. Finally, even the soluble C5b-9 complex has been claimed to 
drive endothelial cells to express increased TF activity [215]. 
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All in all, complement activation on self cells influences the coagulant properties of cells 
in multiple indirect ways. Of greater interest in the context of complement regulation 
are, perhaps, the direct molecular interactions between proteins of the complement 
and coagulation systems, which are discussed below.  
 
2.4.2.2 INTRODUCTION TO DIRECT MOLECULAR INTERACTIONS BETWEEN 
COMPLEMENT AND COAGULATION 
A literature review of the crosstalk between complement and coagulation systems 
reveals that every proteolytic enzyme of the coagulation cascade is capable of cleaving 
at least one protein of the complement system. However, the physiological significance 
of many (if not most) of these interactions is questionable. For example, in in vivo 
settings, the coagulation cascade proteases IXa and Xa function only on negatively 
charged surfaces and in complex with their cofactors VIIIa and Va [216]. It is 
presumable that both the negatively charged surface and the cofactors not only 
enhance the proteolytic efficiencies of the enzymes IXa and Xa, but also affect their 
substrate specificities. Thus, the observation of fluid phase factors IXa, Xa and XIa to 
cleave C3 and C5 in vitro (in the absence of both the negatively charged surface and the 
cofactors) [187] tells us nothing about complement component digestion by these 
coagulation factors on surfaces in vivo.  
Considering substrate selection, it is curious that the proteolytic activity of coagulation 
enzymes has often been tested with native complement proteins (mainly C3 or C5). C3 
is very abundant in plasma [217] and the native form of this protein is without receptor 
activating ability. Thus, when considering complement regulation, degradation of 
native C3 might not be the best of strategies. Instead, further degradation of C3 
activation products, i.e. C3a, C3b and iC3b, appears more reasonable. After all, C3 
fragments are necessarily produced in lower concentrations (compared to the starting 
material C3) and display effector functions by binding to various cell surface receptors 
(see for example [218, 219]).  
In the following, some of the most studied direct molecular interactions between 
complement and coagulation are presented. 
 
2.4.2.3 COMPLEMENT AND THROMBIN 
The key effector enzyme of the coagulation cascade is thrombin, which converts 
soluble fibrinogen molecules into insoluble networks of fibrin fibers. Thrombin is 
mainly produced from prothrombin by the proteolytic action of the prothrombinase 
complex (Xa-Va) during coagulation (Fig. 15). In addition to fibrinogen, thrombin 
activates several other components of the coagulation cascade, including factors V, VIII, 
XI, and XIII.[179, 180] 
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Thrombin is also capable of cleaving complement components, notably C5, at least in 
vitro [187, 220, 221]. However, evidence exist that thrombin-mediated C5 cleavage 
also has physiological relevance. For example, immune complex-mediated induction of 
lung injury in mice was observed to lead to generation of C5a, even though the 
experimental animals were deficient of C3 (and thus formation of the C5 convertases 
C4bC2aC3b and C3bBbC3b was excluded) [222]. Since antithrombin III and hirudin 
prevented C5a generation, cleavage of C5 was attributed to thrombin. Similar to this, 
C5-dependent autoantibody-driven arthritis was not prevented in mice lacking C3, but 
was significantly ameliorated with the thrombin inhibitor argatroban [223]. 
Furthermore, erythrocyte microvesicle-induced C5a generation in mice was observed 
to be lower in the presence of the thrombin inhibitor refludan [224]. Moreover, 
thrombin-mediated C5 cleavage has been speculated to be involved in mobilization of 
hematopoietic stem cells [225]. The effects of C5 cleavage by thrombin are probably 
mediated by C5a binding to its receptor on certain cells [224]. Thus, the thrombin-
mediated cleavage of C5 should probably not be considered as a means of complement 
regulation, but rather as an abduction of the complement protein C5 for signaling 
purposes of other processes. 
The complement factor D was reported to compete with thrombin in binding to platelet 
surfaces, and to thereby inhibit thrombin-mediated platelet aggregation. As the affinity 
of factor D was observed to be lower than that of thrombin, it was concluded that factor 
D could interfere with thrombin binding only in situations in which low thrombin 
concentrations are generated [226]. 
2.4.2.4 COMPLEMENT AND THROMBOMODULIN 
Thrombomodulin is an anti-inflammatory and anti-coagulant glycoprotein expressed 
by endothelial cells of all blood vessels [227]. Although mainly found as attached to cell 
membranes, soluble forms of this regulator also exist and have been found to circulate 
the vasculature [228]. The repeats 5 and 6 of the epidermal growth factor (EGF)-like 
domain of thrombomodulin (EGF5-6) interact with thrombin, preventing this protease 
from, for example, converting fibrinogen to fibrin. The thrombomodulin-thrombin 
complex also activates protein C to APC, which, in turn, hinders coagulation by cleaving 
factors Va and VIIIa.  
Besides restricting coagulation, thrombomodulin also controls the complement 
cascade [227]. For example, thrombomodulin binds directly to C3b and enhances 
inactivation of this fragment by factors I and H [229]. Presumably due to this activity, 
thrombomodulin was observed to enhance C3b inactivation also when expressed on 
chinese hamster ovary cells [229]. The classical and lectin pathways of complement are 
also effected by thrombomodulin, with inhibition of the pathways reported after 
addition of recombinant murine lectin-like domain of thrombomodulin to serum [230]. 
Similar to this, deletion of the lectin domain from thrombomodulin lead to increased 
C3-fragment deposition on mouse podocytes incubated in high glucose serum [231]. 
No role for the lectin domain was, however, observed when porcine endothelial cells 
expressing human thrombomodulin were studied [232]. Instead, the EGF5-6 part of 
thrombomodulin was found to slightly inhibit liberation of C3a and C5a in serum [232]. 
As binding of thrombomodulin to thrombin through EGF5-6 prevents fibrinogen 
conversion by thrombin, it could be speculated that thrombomodulin also impairs C5 
cleavage by thrombin. 
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Thrombomodulin affects complement also indirectly. The thrombin-thrombomodulin 
complex activates the thrombin activatable fibrinolysis inhibitor (TAFI) on vascular 
endothelial surfaces [233]. Activated TAFI, in turn, catalyzes deactivation of C3a and 
C5a, as described in more detail in the next paragraph.  
 
2.4.2.5 COMPLEMENT AND TAFI 
TAFI (or procarboxypeptidase B) removes newly exposed C-terminal lysines from 
partially digested fibrin fibers. This impairs binding of plasminogen and tPA to fibrin. 
Thus, TAFI functions to dampen fibrinolysis; it protects the fibrin clot from premature 
lysis.[233] 
Similar to newly digested fibrin fibers, the newly generated complement activation 
products C3a and C5a carry positively charged residues at their C-termini [234]. 
Whereas in fibrin the last residue is lysine, in the anaphylatoxins it is arginine. Despite 
this, TAFI accepts C3a and C5a as its substrates [235, 236]. Removal of the C-terminal 
residues from the anaphylatoxins results in C3a-des-Arg and C5a-des-Arg. Of these, 
C3a-des-Arg has no pro-inflammatory activity [237], but, depending on the 
experimental setting and the type of cells employed, C5a-des-Arg has been reported to 
induce cell responces ranging from negligible to robust [238]. Besides activated TAFI, 
the constantly active plasma procarboxypeptidase N functions to des-arginate 
complement anaphylatoxis [239, 240]. 
The most potent of the anaphylatoxins, C5a [241], is particularly  efficiently des-
arginated by TAFI in serum [236]. Although this activity was shown to be markedly 
impaired in plasma [236], TAFI-mediated des-argination of C5a possibly has biological 
relevance. For example, in a mouse model of alveolitis, endotracheal instillation of C5a 
was observed to exacerbate pulmonary inflammation in both wt and TAFI-deficient 
mice [242]. Administration of thrombin prior to C5a markedly alleviated the 
inflammation in wt but not TAFI-deficient mice, indicating a role for TAFI in des-
argination of C5a [242]. In line with this, cobra venom factor-induced total complement 
consumption (involves generation of C5a) was observed to lead to a decrease in 
survival of TAFI-deficient but not wt mice which had all been sensitized by 
lipopolysaccharide to express C5aR [243]. 
 
2.4.2.6 COMPLEMENT AND PLASMINOGEN / PLASMIN 
Formation of fibrin is only an intermediate step in hemostasis. After the clot has served 
its function, dissolution of the fibrin network is necessary for restoration of blood flow 
[244]. Fibrinolysis, the process of fibrin digestion, is performed by the protease 
plasmin that is the activation product of the zymogen plasminogen. 
Plasminogen is a 92-kDa glycoprotein that circulates the vasculature at a concentration 
of 0.2 mg/ml or 2 μM. It is composed of a 77-residue N-terminal activation peptide, five 
homologous Kringle domains and a catalytic protease domain (Fig. 16) [244]. The most 
N-terminal amino acid is glutamate, hence the name Glu-plasminogen. Conversion of 
Glu-plasminogen to plasmin involves cleavage of the Arg561-Val562 bond. The 
resulting Glu-plasmin, in turn, removes the inhibiting activation peptide from another 
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Glu-plasminogen, producing Lys-plasminogen. Whereas Glu-plasminogen maintains a 
closed structure with the Arg561-Val562 bond hidden, in the open, more extended 
conformation of Lys-plasminogen the critical bond is easily accessible. Cleavage of the 
Arg561-Val562 bond in Lys-plasminogen by tissue-type plasminogen activator (tPA) 
or urokinase (uPA) produces Lys-plasmin, the enzyme capable of fibrin digestion. The 
conversion of Glu-plasminogen to Lys-plasmin is greatly accelerated on fibrin where 
plasminogen and tPA are brought into close proximity. Furthermore, plasmin is also 
produced on endothelial cells on which Annexin II— S100A10 heterotetramers co-
localize the zymogen with its activators [245].  
Plasmin function is controlled in multiple ways. Cleavage of fibrin leads to exposure of 
lysines at the C-termini of polypeptide chains. These are recognized by the Kringle 
domains present in plasminogen and tPA, leading to increased binding of these 
proteins to the site of fibrinolysis [244] and subsequently, enhanced plasmin 
formation. This enhancement is counteracted by TAFI, which functions to remove 
newly exposed C-terminal lysines from fibrin [233]. Further, the primary physiological 
inhibitor of plasmin is α2-antiplasmin [246]. This inhibitor forms stable inactive 
complexes with free plasmin, i.e. plasmin that is not protected by binding to a surface 
of a cell or fibrin. In addition to circulating the body in plasma, α2-antiplasmin is also 
covalently linked to fibrin to modulate fibrinolysis [247]. Finally, plasminogen 
activator inhibitor 1 exerts its effect indirectly by inactivating the activators of 
plasminogen [248].  
 
 
 
 
 
 
 
Figure 16. Plasminogen is the zymogenic form of the protease plasmin. Plasminogen is composed of an 
N-terminal activation peptide, five homologous Kringle domains and a catalytic protease domain. 
Conversion of plasminogen to the fully active plasmin involves removal of the activation peptide and 
cleavage of the Arg561-Val562 bond [244]. 
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As a zymogen, plasminogen cannot cleave complement components. Some direct 
binding interactions have, however, been described. For example, of the terminal 
complement pathway components, C7 was shown to bind plasminogen, to support 
plasminogen activation by uPA and to protect the resulting protease plasmin from 
inhibition by α2-antiplasmin [249]. Later, in addition to C7, plasminogen was also 
reported to bind C9 [250]. The problem with these studies is that the binding 
interactions employed mainly proteins immobilized onto microtiter plate wells or 
Western blotting paper. The biological function of C7 and C9, however, involves 
insertion in cell plasma membranes as part of the C5b-9 complex. Fortunately, some 
experiments with endothelial cells were also performed [250], and C9 was observed to 
double plasminogen binding  to cells.  
Plasminogen has also been shown to enhance C3b inactivation by factors I and H in the 
fluid phase [251]. However, only a weak enhancement was observed, and this 
necessitated a 500 times molar excess of plasminogen if compared to factor H. Also, a 
negative control was missing from the assay. Based on these results, it can be 
concluded that plasminogen is not involved in C3b inactivation in the fluid phase in 
vivo.  
Unlike plasminogen, the protease plasmin is capable of digesting several complement 
components. Already in 1953, it was described that adding streptokinase (a bacterial 
non-enzyme plasminogen activator [252]) to human serum leads to inactivation of 
mainly C4 and C2 [253]. Later studies have suggested that plasmin activates serum C1, 
which then leads to consumption of C4 and C2 [254, 255]. Subsequently, cleavage of 
C3, C3b, iC3b, C3a and C5 by plasmin has also been described [187, 188, 220, 251, 256-
260]. Inactivation of the complement inhibitor C1-INH by plasmin (for example [261]), 
however, only occurs if C1-INH is denatured; otherwise C1-INH functions as an 
inhibitor of plasmin actions [262]. 
The interactions between plasminogen/plasmin and complement have also been 
investigated in the context of bacteria. Most of the studies show that plasminogen 
bound to bacterial surfaces [263] or to wells coated with bacterial proteins [264-269] 
can be activated to plasmin by adding uPA, and that the resulting plasmin has some 
(most often extremely weak) proteolytic activity towards C3, C3b or C5. When C3b is 
first deposited on bacterial spores [270] or well-coated bacteria [271] using serum, 
and only then plasminogen is added and activated to plasmin with uPA, cleavage of C3b 
also occurs. Furthermore, the Staphylococcus aureus proteins Sbi and Efb were shown 
to enhance plasmin-mediated cleavage of C3 and C3b [256], although the effect was 
barely detectable. Finally, the plasminogen-binding protein CipA of Acinetobacter 
baumannii was observed to inhibit activation of the alternative pathway of 
complement, but whether plasminogen/plasmin were involved, cannot be deduced 
from the results [272].  
All in all, the ability of plasmin to cleave several complement components mainly in the 
fluid phase is rather well established. However, the critical question of whether 
plasminogen binding and activation to plasmin provides surfaces with additional 
protection from complement, remains. 
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2.4.2.7 MASPs AND COAGULATION  
In contrast to the above described ways in which coagulation proteases affect 
complement proteins, a reversed state of affairs prevails with MASPs and the 
coagulation cascade [273]. Namely, MASPs are capable of cleaving several coagulation 
factors, including prothrombin, fibrinogen, XIII and TAFI [274]. 
When MBL-MASP or ficolin-MASP complexes (bound to affinity resins) were exposed 
to diluted plasma, clot formation ensued [275]. Both MASP complexes were found to  
be capable of fibrinogen digestion, but major inhibition of cleavage by hirudin revealed 
that MASPs presumably activated prothrombin to thrombin, which was then 
responsible for fibrinogen conversion [275]. MASP-1 has later been confirmed to be 
capable of converting prothrombin to thrombin [274], although the activating 
cleavages differ somewhat from those performed by Xa [276, 277]. Similarly, 
incubation of truncated MASP-2 with prothrombin leads to measurable thrombin 
activity [278]. However, considering that the positive control in these MASP-2 assays 
was Xa (without the negatively charged surface and cofactor Va, both necessary for 
proper function of Xa), and yet the efficiency of MASP-2-mediated prothrombin 
conversion seemed very modest compared to the positive control Xa [278], it is 
questionable whether MASP-2 has any role in thrombin activation in vivo.  
2.5 REGULATION FAILURE: aHUS 
Activation of the complement system is necessary for several bodily processes to occur. 
Propagation of the complement cascade leads, however, to generation of several 
activation products with, for example, very potent proinflammatory capability (C5a) 
or capacity to cause cell destruction (C5b-9). Thus, precise regulation of the system is 
essential. The importance of stringent control is highlighted by the notion that nearly 
half of the complement proteins serve a regulatory function. If the delicate balance 
between activation and restriction of complement propagation is disturbed, the system 
may be tipped towards self-attack. Should this happen, the consequences can be 
devastating, as demonstrated by the disease atypical hemolytic uremic syndrome 
(aHUS).[279]    
2.5.1 THE RARE THROMBOTIC MICROANGIOPATHY aHUS 
Thrombotic microangiopathies are characterized by hemolytic anemia, thrombo-
cytopenia and organ dysfunction. Endothelial injury is generally considered central in 
inciting and sustaining the microangiopathic processes. The lesions involve vessel wall 
thickening, swelling and detachment of cells from the basement membrane, formation 
of thrombi in arterioles and capillaries, and obstruction of vessel lumina. In HUS, 
kidney is the organ mainly affected, but extrarenal manifestations can also be 
involved.[280] 
Over 90% of HUS cases are caused by Shiga-toxin producing enterohemorrhagic 
Escherichia coli (STEC or EHEC) [281], most notably the E. coli strain O157:H7. In the 
atypical form of the disease, no preceding illness due to STEC can be observed. Instead, 
aHUS can be triggered by several other events, including infectious agents other than 
STEC, malignancy, transplantation, drugs, and pregnancy [282]. Disease onset is 
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generally sudden, and can occur at any stage of life from birth to fairly old age. Female 
sex is slightly over-represented, but only in adult subjects. aHUS has a very poor 
prognosis, with about half of the child patients and two thirds of the adult patients 
progressing either to end-stage renal failure or death [282].  
2.5.2 aHUS AND COMPLEMENT DYSREGULATION 
Initial hints of involvement of complement activation in aHUS were reported in the 
1970’s. First, the concentration of serum C3 was observed to be decreased with a 
simultaneous increase in C3 breakdown products [283]. Soon after, renal deposits of 
C3 were reported in one case. The C4 level of the patient was normal, suggesting 
involvement of the alternative pathway of complement [284]. However, it was not until 
a linkage study in 1998 that FH abnormalities were demonstrated in aHUS etiology 
[285]. 
Although mutations in the regulator FH remain most frequent [282, 286-288], 
malfunction of several other complement proteins has also been associated with aHUS. 
Mutations in the genes encoding complement cascade proteins can be demonstrated in 
roughly two thirds of aHUS patients [282]. In addition to this, in several cases 
autoantibodies against FH can be detected [282]. Currently the syndrome aHUS is 
considered a disease of complement alternative pathway dysregulation [289].  
In the following sections, the genetic abnormalities associated with aHUS are described 
in general. Those interested in the exact amino acid changes related to the specific 
mutations are referred to the aHUS database (www.fh-hus.org) kept by the group of 
Professor Stephen Perkins (University College London).  
2.5.2.1 FACTOR H ABNORMALITIES IN aHUS 
Although not necessary for FH function in the fluid phase, the two most C-terminal 
domains of FH (i.e. CCPs 19-20) are critical for FH function on surfaces [47, 48]. 
Namely, the C-terminus is responsible for the discrimination between self and foreign 
surfaces. Therefore it is not surprising that FH mutations have been observed to cluster 
within the C-terminus of the regulator [290-292]. Studies have shown that the aHUS-
associated mutations in FH19-20 impair FH function on cells [90, 138]. 
Similar to mutations in FH19-20, autoantibodies directed against the C-terminus of FH 
can disturb the function of this regulator on cell surfaces [293]. Anti-FH autoantibodies 
mimic the effects of FH mutations: they impair complement regulation by blocking the 
C-terminal binding sites on FH [294]. Several publications report anti-FH 
autoantibodies in aHUS [287, 293-303]. The estimated incidence of autoantibodies in 
the syndrome varies between 6 and 10% [282]. When anti-FH autoantibodies are 
detected in an aHUS patient, a concurrent deficiency of factor H related proteins 1 and 
3 (FHR1 and FHR3) is usually observed [302]. It has been suggested that this 
correlation could be related to the very small structural differences between the C-
termini of FH and FHR1 [304]. 
Besides single nucleotide changes and deletions, recombination events between the 
gene of FH and the closely related FHRs have been reported in aHUS. Recombination is 
enabled by homologous sequences, resulting in hybrid genes. For example the gene of 
the FH/FHR-1 hybrid comprises the first 21 exons of FH, followed by the last two exons 
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of FHR-1 [305]. Similar to this, the N-terminus of the FH/FHR3 hybrid protein 
originates from FH, whereas the C-terminus is encoded by the gene of FHR3 [306, 307]. 
The roles are reversed for the FHR1/FH hybrids: these contain an N-terminal FHR1-
part linked to a C-terminal portion of FH origin [308, 309]. The association of the hybrid 
proteins with aHUS is presumably due to the following: When the original C-terminus 
of FH is missing (as in FH/FHR3), the hybrid is not directed onto self surface-bound 
C3b. When the original N-terminus of FH is missing (as in FHR1/FH), no regulatory 
function can be performed by the hybrid protein.  
Although most abnormalities causing FH dysfunction in aHUS are related to the C-
terminus, mutations in the functionally important N-terminus of FH have also been 
associated with aHUS. For example, the mutations R53H and R78G have been reported 
to impair both cofactor and decay-accelerating abilities of FH [310]. It is curious that 
the mutation R53H was linked to aHUS, since it was observed to impair FH cofactor 
activity also in the fluid phase, and fluid phase dysregulation of the alternative pathway 
of complement is generally associated with membranoproliferative glomerulo-
nephritis type II (i.e. dense deposit disease) [311].  
aHUS with complete deficiency of FH has also been reported. Total lack of FH involves 
homozygous genetic abnormalities [312, 313]. In contrast to this, the majority of FH 
mutations linked to aHUS appear in heterozygosity. This is true also of mutations in 
other genes. Furthermore, in several cases, a combination of two or more mutations in 
different genes can be detected [282, 287, 314]. Finally, the subjects with FH mutations 
have the most severe prognosis among patients with aHUS [286, 288, 315].  
 
2.5.2.2 FACTOR I MUTATIONS IN aHUS 
Inactivation of C3b to iC3b necessitates assistance provided by a cofactor (FH, MCP, or 
CR1), but the actual proteolytic cleavage of C3b is performed by the serine protease FI. 
Thus, it is not surprising that several mutations in the gene encoding FI have also 
become associated with aHUS (see for example [315-317]). Many of the mutations in 
FI result either in low level of the protease in serum [316, 318] or /and impaired 
proteolytic function [319, 320]. In some cases, no abnormality due to a mutation in FI 
can be detected, and the concurrent aHUS-associated polymorphisms in FH are more 
likely to explain the disease in these patients [321]. 
Similar to FH, autoantibodies against FI have also been reported in aHUS. However, no 
correlation between anti-FI autoantibody titer and disease activity could be observed 
[322]. 
2.5.2.3 MEMBRANE COFACTOR PROTEIN MUTATIONS IN aHUS 
In patients with aHUS, mutations have also been described in the membrane-bound 
complement regulator MCP. The mutations seem to affect mainly MCP expression, 
leading to reduced levels of MCP on cell surfaces in the affected individuals [323-328]. 
MCP mutations are associated with the mildest form of aHUS [286, 288, 315]. 
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2.5.2.4 C3 MUTATIONS IN aHUS 
In contrast to the loss-of-function mutations reported in complement regulators, 
genetic abnormalities of complement C3 in aHUS result in enhanced protein function. 
The resulting increased complement activity often, but not always, translates into 
augmented C3 consumption leading to low C3 levels in serum [329-333]. The 
mutations have been reported to have variable effects on C3 function. On the one hand, 
enhanced factor B binding and convertase formation can occur [332, 334]. On the other 
hand, reduced binding to one or several of the cofactors (FH, MCP or CR1) leads to 
increased resistance against C3b inactivation and convertase decay [331, 333-337]. 
Some mutations have even been reported to enable binding of factor B to the 
inactivated C3-fragment iC3b [331].  
2.5.2.5 FACTOR B MUTATIONS IN aHUS  
Mutations in the complement factor B have also been associated with aHUS [338-341]. 
Investigation of the effects of mutations in FB have shown that in some cases, C3bB 
complex formation is more rapid for mutant than wt FB molecules. With mutant FB the 
convertase C3bBb can also display enhanced functional activity or be more resistant to 
decay [342, 343].  However, it has also been reported that no significant functional 
abnormality was observed for a total of seven FB mutations in one study [343]. This 
can be considered somewhat unexpected, and thus calls for further experimentation. 
For example, could the mutations in FB somehow affect C3b interactions with 
properdin? 
 
2.5.2.6 aHUS MUTATIONS IN PROTEINS OTHER THAN THOSE OF THE 
COMPLEMENT SYSTEM 
Considering the thrombotic nature of aHUS, it is not surprising that mutations in 
proteins relevant for coagulation and fibrinolysis are increasingly becoming associated 
with the syndrome. One example is the anticoagulatory protein thrombomodulin. 
Whereas reduced complement regulation due to aHUS-associated mutations in this 
glycoprotein has been confirmed [229], impairment of complement control by 
mutations in other non-complement proteins appears less likely. For example, the 
association of plasminogen deficiency with aHUS could simply be due to impaired 
fibrinolysis [344]. Furthermore, even though deficiency of coagulation factor XII was 
reported in one aHUS case [345], the lack of XII need not have been involved in disease 
pathogenesis in this patient, since the pathogenesis could be explained with the 
concurrent presence of anti-FH autoantibodies. Finally, some aHUS patients have been 
reported to carry mutations in the gene encoding diacylglycerol kinase epsilon (DGKε) 
[346, 347]. DGKε is involved in cell signaling and normally functions to prevent protein 
kinase C from driving cells towards a prothrombotic state. Loss of DGKε function leads 
to increased TF expression and apoptosis in endothelial cells, but does not seem to 
augment complement activation [348]. 
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2.6 COMPLEMENT DYSREGULATION IN aHUS: 
FROM DETAILS TO THE BIG PICTURE 
Research related to the pathogenic mechanisms of the disease aHUS is multifaceted. At 
the one extreme, there are crystallographic structures revealing the amino acid 
residues that are responsible for interactions between different proteins. At the other 
extreme, there are reports on the effectiveness of the drug eculizumab in treatment of 
aHUS patients with varying underlying causes. All in all, information related to aHUS is 
available in abundance. However, we still lack a thorough understanding of several 
aspects of the disease. This literature review is concluded with an overview of some of 
the questions that still remain unanswered. With this, the reader will be better able to 
see how the work presented later on in this thesis relates to previous knowledge of 
aHUS. 
 
 
 
 
 
 
 
Figure 17. Abnormalities in aHUS cluster at the C3 conversion step of the complement cascade. The 
complement cascade is presented with an arrow chart with the C3 step highlighted in black. Mutations 
leading to gain-of-function are shown in green and those resulting in loss-of-function in red. The effect of 
each mutation on the function of the protein in question is described in light grey.  
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2.6.1 FIRST FOCUS: THE DYSREGULATED STEP 
The pathogenic mechanisms involved in aHUS remain poorly described in many ways. 
For example, excessive complement activity has been shown to be involved in the 
disease, but the events triggering the imbalance of complement control continue to be 
unclear. In contrast to this, the general defect underlying complement dysregulation is 
fairly well described. 
When considering the different complement-related abnormalities reported in aHUS – 
ranging from anti-FH autoantibodies to thrombomodulin mutations – there seems to 
be, at the first glance, great variation. However, placing the abnormalities 
simultaneously in an arrow chart of complement cascade function forces one to make 
an important observation: all the defects have the same net effect of increasing 
complement activation at the step of C3 conversion (Fig. 17). Whether an FB mutation 
causing enhanced stability of the C3bBb convertase or an anti-FH autoantibody 
preventing FH-mediated complement regulation on cells, an increase in C3 conversion 
is involved. In other words, different abnormalities in aHUS all lead to complement 
dysregulation by reducing the control over the C3 step of the complement cascade. 
 
 
 
2.6.2 ZOOM IN: MISSING MOLECULAR DETAILS 
Although the various complement abnormalities associated with aHUS are known to 
lead to excess complement activity at the C3 step, several pieces of the puzzle 
describing the detailed molecular mechanisms involved are still missing. Take, for 
example, the most frequently mutated protein in aHUS, the regulator FH. Similar to 
most plasma proteins, FH is glycosylated. Even though the glycans are not necessary 
for FH function, could they somehow guide FH in binding to C3b? The middle part of 
FH (domains 9-18), which harbors the glycosylations, is interesting in the context of 
aHUS. Namely, some patients have been reported to present with mutations in this part 
of the FH molecule. One could ask, for example, whether the FH domains 9-18 are 
responsible for positioning the N- and C-termini of FH appropriately during C3b 
inactivation and whether they bind C3b directly. Then, how about the domains 6-8 of 
FH? Even though the C-terminus of FH is the part that is critical for FH binding to cells 
with no mutations in domains 6-8 reported in aHUS, FH6-8 could nevertheless assist 
FH in binding to, for example, endothelium. If so, how do FH domains 6-8 and 19-20 
exactly cooperate? This leads us to the question of the “choreography” of C3b 
inactivation: Does one FH molecule interact with only one surface-bound C3b or are 
multiple C3bs involved? Indeed, an endless list of questions on the molecular biology 
of FH can be generated. But perhaps in the context of current aHUS research, the issue 
of the self surface marker for FH stands out above others. In general, 
glycosaminoglycans are thought to be responsible for interactions of FH with cells. The 
experimental data does not, however, support this view. So, the question remains: what 
is the cell surface structure responsible for attracting FH onto self cells under 
complement attack?  
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2.6.3 ZOOM OUT: THE BLURRY BIG PICTURE 
Similar to missing several details of complement regulation at molecular level, also the 
big picture of the disease mechanism of aHUS appears blurry. Importantly, it remains 
unclear, how complement dysregulation is exactly interwoven in aHUS pathogenesis 
(Fig. 18). In other words, the interactions between complement and the other “entities 
of the body” in aHUS need further clarification. Some aspects of this issue are discussed 
below. 
 
 
Fig. 18. Locating complement activation/dysregulation in a simplified diagram of aHUS. The questions 
marked with grey are discussed in detail in the main text.  
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2.6.3.1 TIPPING THE BALANCE 
In aHUS, complement deposition has been shown on both glomerular endothelial cells 
and platelets, suggesting involvement of complement attack on these types of cells in 
the pathogenesis of the disease. But how is the balance between activation and 
inhibition of the complement cascade tipped towards too much activity?  
With endothelial cells, it has been suggested that the release of complement-activating 
microvesicles from cells could initiate complement activation [349]. Namely, the 
calcineurin inhibitor drug cyclosporine [350], which has been associated with aHUS, 
was observed to cause microvesicle release from endothelial cells [349].  However, 
even though cyclosporine was clearly shown to induce significantly increased C3 
deposition in mouse glomeruli, the complement-activating ability of the microparticles 
released due to cyclosporine was not that convincing. Perhaps more likely is that 
cyclosporine – or some other trigger – causes direct damage to endothelial cells and 
thereby augments complement activation on them. Having stated this, it is somewhat 
difficult to envision the ways in which, for example, an upper respiratory tract infection 
could cause significant harm to the endothelia of kidney glomeruli.  
With erythrocytes, the question of tipping of the balance of complement regulation 
towards too much activity is perhaps more complicated. Whereas on endothelium the 
nephrotoxic drug cyclosporine, for example, can induce serious cell damage, with 
erythrocytes this is likely not the case. Namely, erythrocytes lack cell organelles, and 
thus the transcription- and mitochondria-related effects of cyclosporine cannot occur. 
Instead, it could be hypothesized, that complement activation would spread onto 
erythrocytes from endothelial cells in the very narrow capillaries of the vascular 
system. 
2.6.3.2 THE MECHANISM OF HEMOLYSIS 
One characteristic feature of aHUS is lysis of erythrocytes. Hemolysis in aHUS is 
generally considered to be mechanic with narrowing of the capillaries leading to 
erythrocyte rupture. This assumption has not, however, been experimentally proven. 
Thus, a role for complement in hemolysis in aHUS cannot be excluded. Propagation of 
the complement cascade up to the level of C5b-9 deposition could be involved. 
Alternatively, complement could have a mere enhancing effect. Namely, deposition of 
complement on erythrocytes has been shown to cause stiffening of these cells. It could 
be that surface deposition of complement on erythrocytes predisposes them for 
rupture in narrowed capillaries.  
Regardless of the mechanism of hemolysis in aHUS, erythrocyte rupture leads to 
liberation of heme from the cells to the blood. Heme enhances complement activation, 
and thus hemolysis could augment complement-mediated damage to endothelial cells 
in aHUS [351]. 
2.6.3.3 THE HARMFUL COMPLEMENT 
Propagation of the complement cascade leads to formation of several potentially 
dangerous, bioactive products. But which one(s) are responsible for the consequences 
of the loss of complement control in aHUS? The various C3 fragments are unlikely to be 
the answer, since the drug eculizumab, an effective treatment for aHUS, exerts its 
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complement inhibitory effect only at the level of C5. This leaves C5a and C5b-9 as the 
main candidates for mediators. But what effects do they bring about and in which types 
of cells? At least deposition of C5b-9 is restricted to the site of complement activation, 
suggesting endothelial cells and platelets to be of major importance in aHUS. Central 
role of these cells in the disease pathogenesis is further supported by the fact that both 
endothelial cells and platelets express DGKε, the deficiency of which results in a 
prothrombotic state and is thought to underlie disease mechanisms in the 
complement-independent DGKε-aHUS. So, do C5a recognition and/or C5b-9 deposition 
on endothelial cells and platelets have the same net effect on the function of these cells 
as the deficiency of DGKε does? 
2.6.3.4 ERYTHROCYTES IN THROMBUS FORMATION 
Formation of fibrin-rich thrombi in the microvasculature is a characteristic feature of 
aHUS. The role of endothelial cells and platelets in thrombus formation in general is 
well established, with the erythrocytes largely neglected. However, recent data suggest 
that the part played by erythrocytes has likely been much underestimated. Namely, it 
seems that the erythrocytes are involved in thrombus formation by providing the 
surface platform for components of the coagulation system. This raises the question of 
putative complement-coagulation crosstalk on erythrocytes, as discussed next. 
2.6.3.5 CROSSTALK WITH THE COAGULATION SYSTEM 
Studies on thrombomodulin have shown that mutations in coagulation system proteins 
can also underlie complement dysregulation. The most recent example of an aHUS-
associated coagulation system protein is plasminogen, with four aHUS patients 
described to present with deficiency of this protein. Since the protease form of 
plasminogen, or plasmin, is a fibrinolytic enzyme, the link between aHUS and 
plasminogen deficiency has been explained by impaired fibrinolysis. However, plasmin 
is known to digest several complement components, and even the zymogen 
plasminogen has been reported to display a weak enhancing effect on C3b inactivation. 
This raises the following question: could the association of plasminogen deficiency 
with aHUS be due to reduced complement control instead of (or in addition to) 
defective fibrinolysis?  
The idea of coagulation proteins acting on complement factors is by no means new. The 
crosstalk between the complement and coagulation system proteins has been studied 
since the 1950’s. Unfortunately, however, most research has been performed using 
purified, artificially activated coagulation factors. Therefore, very little can be said 
about whether or how the coagulation cascade members would affect complement 
propagation under physiological conditions.  
Whereas research on complement-coagulation crosstalk has mainly concentrated on 
answering how coagulation factors affect complement proteins, the question could 
(and should) also be reversed. Namely, very little is currently known about the ways 
in which complement factors affect the coagulation system. The optimal approach 
would be, of course, to study how complement and coagulation systems affect each 
other, when both cascades are simultaneously activated on natural cell surfaces under 
physiological conditions. 
47 
 
3 AIMS OF THE STUDY 
The thrombotic microangiopathy atypical hemolytic uremic syndrome (aHUS) features 
excess complement activation, and is the clinical manifestation of impaired regulation 
of the complement system. In aHUS, the interplay between blood and vascular cells and 
the complement and coagulation cascades is pathogenically important.  
The general aim of the work described in this thesis was to shed new light on the 
mechanisms of control of complement cascade propagation on surfaces of 
erythrocytes, endothelial cells, and platelets, the types of cells implicated in aHUS. The 
focus was on the complement inhibitory mechanisms exerted by the complement 
regulator factor H (FH) and the fibrinolytic precursor plasminogen, both of which have 
been associated with aHUS due to genetic abnormalities. 
 
The specific aims of the three different projects were the following: 
 
I. to better describe the binding interactions between the C-terminus of FH 
(FH19-20) and malondialdehyde (MDA)-modified proteins and peptides (SI) 
 
II. to determine whether or not plasminogen is important for complement 
regulation on cell surfaces capable of binding and activating this zymogen (SII) 
 
III. to investigate whether sialic acid is involved in FH-mediated complement 
regulation on endothelial cells and platelets (SIII) 
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4 MATERIALS AND METHODS 
4.1 MATERIALS  
Information on the manufacturers of the commercial products and on the preparation 
of the self-produced materials relevant to this work can be found in the original articles 
(SI, SII or SIII).  
4.2 METHODS  
The methods used in this work have been listed in table 2. More detailed descriptions 
of how the assays were carried out can be found in SI, SII, SIII, or in the text below. 
Some methods expected to be less familiar to many researchers in the complement 
field have been illustrated with photographs below.  
4.2.1 SYNTHESIS OF THE SODIUM SALT OF MDA 
MDA-modifications of proteins are generally performed using the sodium salt of 
malondialdehyde (Na-MDA). Unfortunately this reagent is not commercially available, 
probably due to it being somewhat reactive. The company Sigma-Aldrich sells the 
tetrabutylammonium salt of MDA (tba-MDA), but usage of this chemical in MDA-
modification of proteins had not been documented. As resorting to a cheap, readily 
available commercial substitute was seen as an alluring alternative to the cumbersome 
preparation of MDA in-house, it was decided that Na-MDA be produced, and then 
compared with the commercial tba-MDA in its ability to modify BSA. 
Na-MDA was synthesized in the laboratory of organic chemistry in the Aalto University 
under supervision of Professor Reija Jokela mainly as previously described [153]. 
Briefly, the start material 1,1,3,3-tetramethoxypropane was acidified with HCl, 
followed by a 1 hour incubation to allow formation of MDA (Fig. 19). NaOH and ice-
cold acetone were added to precipitate Na-MDA. The salt was recovered by filtration 
and then washed using cold acetone, followed by vacuum drying. The powdery product 
(Na-MDA) was stored at -20°C. 
 
 
Figure 19. The malondialdehyde sodium 
salt was synthesized in the organic 
chemistry laboratory in the Aalto 
University. Left: The liquid compound 
1,1,3,3-tetra-methoxypropane was 
used as the start material. Right: The 
sodium salt of malondialdehyde is a pale 
yellowish powder. 
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Table 2. Methods employed in Studies I-III.  
METHOD STUDY 
Synthesis of the sodium salt of MDA (Na-MDA) SI 
Synthesis of hexyl-MDHDC from hexylamine using self-prepared Na-MDA SI 
Modification of proteins and (poly)peptides with MDA SI 
Modification of BSA with acetic anhydride SI 
Cloning of the FH domains 6-8 (starting with the human cDNA liver library) SI 
Introducing an HA-tag to the N-termini of FH fragments FH6-8 and FH19-20 
(through mutagenesis) 
SI 
Analysis of FH19-20 binding to microtiter plates coated with MDA-modified 
proteins or peptides 
SI 
Analysis of FH19-20 binding to heparin beads in the presence of MDA-modified 
BSA 
SI 
Analysis of FH19-20 binding to DNA in the presence of MDA-modified BSA 
(gel-shift assay) 
SI 
Mass spectrometry analysis of MDA-adduct sizes of MDA-modified peptides SI 
Preparation of fibrin-coating in microtiter plate wells SII 
Preparation of fibrin particles SII 
Analysis of serum complement activation using a commercial C3a detection kit SII 
Analysis of residual serum complement activity (lysis of sensitized sheep 
erythrocytes in serum) 
SII 
Hemolysis assays with sensitized sheep and human erythrocytes SII, SIII 
Complement activation on human umbilical vein endothelial cells (HUVECs; 
analysis of C5b-9 insertion by calcein release) 
SII, SIII 
Complement activation on HUVECs (analysis of C3b deposition by flow 
cytometry) 
SII, SIII 
Complement activation on platelets (analysis of C3b deposition by flow 
cytometry) 
SII, SIII 
Platelet aggregation assays SII 
Microscale thermophoresis (MST) assays (analysis of protein-sialic acid 
interactions) 
SIII 
Natural deposition of C3b on beads, erythrocytes and endothelial cells SIII 
Protein binding assays with several types of cells (detection by flow 
cytometry) 
SIII 
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4.2.2 SYNTHESIS OF HEXYL-MDHDC 
Unlike Na-MDA, hexyl-MDHDC was available from a commercial source. The price was, 
however, astronomical and therefore also hexyl-MDHDC was produced in-house (Fig. 
20). Mainly as previously described [155], MDA was combined with hexylamine, and 
the pH was lowered to 4 using HCl. Acetaldehyde was added and the mixture was 
stirred for 2 hours at 50°C to allow formation of hexyl-MDHDC. The aqueous solvent 
phase was removed with vacuum. The organic residue was dissolved in 
dichloromethane and washed twice with water to remove any residual acid. 
Anhydrous Na2SO4 was used to get rid of any traces of water, and the sample volume 
was reduced with vacuum. Then a silica column was prepared, and the sample was run 
through the column using methanol:dichloromethane (1:9) as the running phase. 
Several outflow fractions were collected and analyzed for their hexyl-MDHDC content 
by thin layer chromatography. The fraction containing hexyl-MDHDC was dried with 
vacuum, giving a flaky orange-yellow end product. Later, 1H NMR analysis was 
performed to confirm that the product truly was hexyl-MDHDC. 
 
 
Figure 20. Left: Hexyl-MDHDC was synthesized by incubating malondialdehyde with hexylamine at 
suitable conditions. Middle three pictures: The desired compound was separated from unwanted 
material by multiple purification steps. Right: The orange-yellow flakes of the pure end product hexyl-
MDHDC.  
 
4.2.3 MODIFICATION OF PROTEINS WITH MDA 
MDA modification of proteins was performed mainly as previously described [153, 
352]. Briefly, protein in 100 mM phosphate (pH 7.2) was mixed with MDA (dissolved 
in water), and rotated at 37°C for 17 hours. In some modifications, acetaldehyde was 
included in the modification reactions in order to enhance formation of MDA adducts, 
especially the formation of MDHDC. To stop the modification reactions and to remove 
any unreacted aldehydes, the modified proteins were exchanged to PBS using either 
gel filtration or centrifugal filtering.  
Heavy modification of proteins with MDA was observed to turn them vividly yellow 
(Fig. 21). They also started to display intense fluorescence. This was due to MDA 
modification introducing fluorescent MDHDC adducts to the proteins [353]. 
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Figure 21. Left: Extensive modification of BSA with 
malondialdehyde transforms this colorless protein into a yellow 
product. Movement of a concentrated MDA-modified protein in a 
gel filtration column can thus be followed with bare eyes. Middle: 
MDA-BSA shows intense fluorescence and was therefore 
detected along with the narrow ethidiumbromide-stained DNA 
band in a gel shift assay. Right: The MDHDC adduct in hexyl-
MDHDC shows strong fluorescence when exposed to UV light on 
a thin layer chromatography sheet. Four different samples were 
analyzed.  
 
4.2.4 BINDING ASSAYS WITH THE HA-TAGGED FH19-20  
Microtiter plate wells were coated with MDA modified BSA (10 µg/ml). Native BSA was 
used as a control. Wells were blocked with 0.5% BSA. Mutant or wt FH19-20 fragments 
were mixed 50:2.5 with the HA-tagged wt FH19-20. 100 µl of these FH19-20 mixtures 
were incubated in MDA-BSA-coated wells. Wells were washed and the bound FH19-
20HA detected with rabbit anti-HA tag antibody (GeneTex) and an HRP-conjugated 
anti-rabbit-antibody (Jackson ImmunoResearch Laboratories). The plates were 
developed with OPD substrate and H2O2 according to manufacturer’s instructions. 
Absorbances were measured at 492 nm. 
4.2.5 PREPARATION OF FIBRIN PARTICLES 
Artificial fibrin surfaces can be produced by coating fibrinogen onto microtiter plates 
and then cleaving fibrinogen molecules with thrombin (see for example [354]). 
Although surface-bound fibrinogen takes a conformation resembling that of cleaved 
fibrinogen, this kind of a 2-D fibrin is presumably not representative of the 3-D 
networks present in fibrin fibers. Therefore fibrin particles were also produced. 
Fibrinogen was diluted in a buffer and human thrombin was added. The mixture was 
incubated in rotation at 37°C for 1 hour. The clot was frozen on dry ice and then 
lyophilized for 44 hours. The resultant dry fibrin clot (Fig. 22) was ground into very 
fine powder with a pestle and a mortar. 
The resulting fibrin particles were very hydrophobic, and could not be handled in plain 
PBS without major losses due to particle binding to tube walls and pipet tips. Therefore 
all assays with fibrin particles were performed in PBS containing 1 mg/ml BSA. 
 
Figure 22. An artificial 
fibrin clot was prepared 
from fibrinogen using the 
protease thrombin. The clot 
was lyophilized to dryness 
(resulting in the white “rod” 
faintly visible at the bottom 
of the tube). 
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4.2.6 COMPLEMENT ACTIVATION ON ENDOTHELIAL CELLS  
Human umbilical vein endothelial cells (HUVECs; 3×105 in a final volume of 100 µl) 
were preincubated with or without plasminogen (0.2 mg/ml) in PBS at 22°C for 10 
min. Serum was added to a final concentration of 10 %. As the complement system of 
serum of healthy humans does not activate against HUVECs on its own, complement 
activation needed to be started with the anti-CD59 antibody YHT53.1 (0.1 mg/ml) 
[355]. Cell samples were incubated for 30 min at 37°C. In the C3b-assay, C3 labeled 
with NT-647 (NanoTemper Technologies, GmbH; 0.1 mg/ml) was included in the 
serum incubation. In the C5b-9-assay, cells were washed after the serum treatment 
with PBS and then incubated with NT-647-labeled anti-C5b-9 antibody for 25 min at 
22°C. Binding of fluorescently labeled proteins to HUVECs was determined by flow 
cytometry (using the CyAn™ ADP Analyzer).  
 
4.2.7 PLATELET AGGREGATION ASSAYS WITH VERY SMALL SAMPLE 
VOLUMES 
Ordinary platelet aggregation assays with traditional aggregometers necessitate serum 
volumes of approximately 300-500 µl. Such large quantities can become a problem 
when valuable reagents are scarce. For this reason, platelet aggregation assays were 
performed with a microtiter plate reader equipped with shaking and heating options 
(Fig. 23). By doing this, we were able to reduce the sample volume requirement 
significantly below 100 µl. Further, resorting to the microplate reader increased 
remarkably the number of samples that could (theoretically) have been analyzed 
simultaneously (from 4 to 96).  
 
 
Figure 23. When  double orbital shaking mode with 
heating options are selected, an ordinary microtiter 
plate reader (FLUOstar OPTIMA, BMG Labtech) changes 
into a platelet aggregometer with very small sample 
volume requirements and a remarkably increased 
capacity.  
 
 
 
 
 
4.2.8 MICROSCALE THERMOPHORESIS  
Microscale thermophoresis (MST) is a fairly new analysis technique, which can be used 
to study binding interactions between biomolecules in very small volumes and in the 
fluid phase [356]. In order to perform a thermophoresis experiment with the 
NanoTemper equipment (Monolith NT.115Pico), the first partner of the binding 
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interaction under investigation needs to be fluorescently labeled. A dilution series with 
a wide concentration range is prepared of the second partner. Then, the fluorescently 
labeled first partner, usually a protein, is mixed with the dilution series of the unlabeled 
second partner (or the ligand). Samples are transferred into very small glass capillaries 
for analysis (Fig. 24). In the actual measurement, a tiny little sample volume within 
each capillary is heated with a laser. This causes movement of fluorescently labeled 
molecules into or out of the heated spot. The movement in the thermal gradient 
between the heated spot and the cooler surroundings is followed by measuring 
fluorescence of the labeled target as a function of time (30 seconds). As a result, a 
thermogram for each ligand concentration is obtained. These data can then be used to 
fit a binding curve and to calculate a dissociation coefficient for the interaction. 
In Study III, MST was used to study the interaction of FH with sialic acid. As for the sialic 
acid containing ligand, 3’sialyl lactose was chosen, for it had previously been shown 
that this trisaccharide interacts with FH19-20 in at least NMR and X-ray crystals [58]. 
FH and the positive control Maackia amurensis lectin II (MAL II) were labeled 
fluorescently with NT-647. The 3’sialyl lactose dilutions ranged from 1.5 µM to 50 mM. 
When performing thermophoresis, the LED and MST powers were set to 10% and 80%. 
 
 
 
 
 
 
 
 
 
 
Figure 24. Microscale thermophoresis (MST) is a fairly new technique to study protein binding. 
Left: Fluorescently labeled protein is mixed with a range of unlabeled ligand concentrations, and 
samples are transferred to very thin glass capillaries for measurement. Right: NanoTemper MST-
equipment Monolith NT.115Pico. 
 
 
4.2.9 DEVELOPMENT OF A CALCEIN-RELEASE ASSAY 
To easily study complement activation on endothelial cells, a calcein-release assay was 
developed. To this end, detached endothelial cells were filled with calcein by incubating 
them with 25 µM calcein-AM for 30 min at 37°C (Fig. 25). After washing the cells, serum 
was added (to a final concentration of 15%). Then, the complement system was 
initiated using increasing concentrations of the anti-CD59 antibody YHT53.1 [355]. 
Triton X-100 was used to enable total lysis in the control sample. After an incubation 
at 37°C, the cells were pelleted by centrifugation. Samples of supernatants were 
analyzed for their calcein content by measuring fluorescence at ex/em values 485/520 
nm.  
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To study whether the anti-CD59-initiated complement activation was vigorous enough 
to cause the calcein-filled cells to lyse, supernatants were studied also for their lactate 
dehydrogenase (LDH) content. Samples were mixed 1:1 with an analysis reagent 
(CytoToxONE kit, Promega) and, after allowing color formation, fluorescence of the 
LDH-indicator resorufin was measured at 540/590 nm. 
The anti-CD59 antibody was observed to cause a dose-dependent increase in the 
supernatant calcein level (SIII/Fig. 6A), indicating that calcein was released from the 
cells. This was not due to cell lysis, since LDH was held within the HUVECs (SIII/Fig. 
6A). During complement attack on a cell surface, C5b-9 complexes are inserted in the 
plasma membrane. Being a very small compound (< 1 kDa), calcein is expected to 
easily escape from the cell through the pore in a C5b-9 complex. LDH, on the other 
hand, is retained inside the cell due to its fairly large size (140 kDa). All in all, it was 
concluded that in the new assay, calcein concentration of the supernatant indicates the 
level of C5b-9 complexes inserted in cell plasma membranes and therefore is a measure 
of the extent of complement activation in the system. 
 
Figure 25.  Calcein-AM readily enters viable, 
naturally colorless endothelial cells. 
Cytoplasmic esterases in cells cleave the AM 
groups off, thereby trapping the fluorescent 
calcein molecules inside the cells, turning 
them vividly greenish yellow. In the photo, the 
cells appear as a tiny yellowish pellet at the 
bottom of the tube. 
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5 RESULTS 
5.1 RESULTS OF STUDY I 
In their search for new plasma proteins displaying affinity for MDA-modified targets, 
Weismann et al. [143] discovered the binding of FH to MDA-BSA.  In Study I, the 
interactions of FH19-20 with MDA modified proteins and peptides were characterized 
in more detail. 
5.1.1 COMMERCIAL MDA IS SUITABLE FOR MODIFICATION OF 
PROTEINS 
The equipment necessary for synthesis of the sodium salt of MDA (Na-MDA) is not 
typically available in a biomedical research laboratory, including ours. Therefore it was 
considered worthwhile to study whether the commercially available tetrabutyl-
ammonium salt of MDA (tba-MDA) could be used instead.  
When BSA was modified with the two different MDA salts, the resulting Na-MDA-BSA 
and tba-MDA-BSA were observed to have nearly identical properties (Fig. 26 and 
SI/Fig. 2). Na-MDA-BSA and tba-MDA-BSA exhibited very similar fluorescence, 
practically equal mobility in native PAGE, and nearly identical binding to both FH and 
the anti-MDHDC. Because no significant differences could be observed, it was 
concluded that the commercial tba-MDA is suitable for MDA modification of proteins. 
 
 
 
Figure 26. Comparison of the binding properties of BSA 
modified with different MDA salts. FH and anti-MDHDC 
antibody display equal affinities for Na- and tba-MDA-BSA. 
 
 
 
 
 
 
 
5.1.2 POSITIVELY CHARGED RESIDUES MEDIATE FH19-20 BINDING 
TO MDA-MODIFIED BSA 
In order to determine the site of FH19-20 responsible for the interactions with MDA-
BSA, binding of wt and several mutant FH19-20 fragments to MDA-BSA was compared. 
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In direct binding assays it was observed that an increase in total positive charge of the 
FH19-20 fragment due to mutations led to an increase in FH19-20 binding to MDA-BSA 
(SI/Fig. 3A). On the contrary, loss of total positive charge caused a decrease in FH19-
20 binding to MDA-BSA. The only exception to the rule was the mutation W1138L. The 
competition assays with HA-tagged FH19-20 gave similar results (Fig. 27). Namely, the 
more positively charged FH19-20 mutants were better able to inhibit FH19-20HA 
binding to MDA-BSA than the wt FH19-20, whereas the less positively charged mutants 
showed impaired ability to compete with FH19-20HA binding. Here statistical 
significances were not calculated, because the competition assay was performed only 
once in triplicate. This was due to the substantial amount of each mutant necessary for 
conducting the assay. 
The interaction of FH19-20 with MDA-BSA was further confirmed to be of ionic nature 
by showing a decrease in FH19-20 binding on increasing the salt concentration of the 
buffer (SI/Fig. 3C). 
Thus, it was concluded that FH19-20 binds MDA-modified BSA mainly using the 
positively charged residues on FH19-20. 
 
 
 
Figure 27. Effect of mutations on FH19-20 
binding to MDA-BSA. In the experimental setup 
used, wt FH19-20 was able to reduce binding of 
the HA-tagged wt FH19-20 to MDA-BSA. The 
ability of several mutant FH19-20 fragments to 
compete with FH19-20HA is also presented. 
Shown are average values ± SD of an assay 
performed once in triplicate.  
 
 
 
 
 
 
5.1.3 BINDING SITES FOR MDA-BSA, HEPARIN, AND DNA ON FH19-
20 OVERLAP 
The pattern with which the mutations were observed to affect FH19-20 binding to 
MDA-BSA (SI/Fig. 3A) was very similar to that reported for FH19-20 binding to heparin 
[90, 138]. Therefore it was asked, if the binding sites for MDA-BSA and heparin on 
FH19-20 show overlap. It was observed that MDA-BSA in the fluid phase was able to 
inhibit FH19-20 binding to heparin beads (SI/Fig. 3A, B). Moreover, MDA-BSA was also 
shown to prevent interactions of FH19-20 with another polyanion, i.e. DNA (SI/Fig. 
3C). Thus, it was concluded that the MDA-BSA binding site on FH19-20 overlaps with 
those for heparin and DNA. 
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5.1.4 FH19-20 INTERACTS WITH THE NEGATIVE CHARGES ON 
MODIFIED BSA 
During MDA modification, proteins become decorated with mainly neutral MDA-
adducts (Fig. 13) [144, 154-157]. Therefore it was somewhat puzzling that FH19-20 
binding to MDA-BSA was observed to depend on positively charged residues and to 
utilize an overlapping binding site with those for the polyanions heparin and DNA. 
While introducing various non-charged adducts into lysine side chains in proteins, 
MDA modification simultaneously removes the positive charges of lysines, thereby 
leading to a net increase in overall negative charge of the modified target. Further, 
unmodified BSA has a great proportion of lysines in its sequence (10%), and carries an 
overall negative charge to start with (pI 5) [357]. Thus, it was asked, whether it was 
this increase in negative overall charge due to MDA-modification (instead of or in 
addition to MDA-adducts) that was responsible for FH19-20 binding to MDA-BSA. To 
answer this question, the positive charges of lysines on BSA were masked by 
acetylation, resulting in A-BSA. When compared to MDA-BSA, A-BSA showed similar 
mobility in native PAGE, suggesting similar overall negativity for MDA- and A-BSA 
(SI/Fig. 5A). A-BSA was then observed to bind FH19-20, although not as efficiently as 
MDA-BSA (SI/Fig. 5C).  
The role of negative charges on MDA-BSA in binding to FH19-20 was further studied 
using seven new proteins with different pI values. As the pI value of a protein increases, 
the pH (of the buffer) at which the overall charge of the protein changes to be negative 
increases. When the seven new proteins were modified with MDA and then coated on 
a microtiter plate, they showed very similar binding to anti-MDHDC antibody, 
suggesting approximately equal levels of MDA adducts (SI/Fig. 5D). However, binding 
of FH19-20 was observed to decrease with increasing pI of the modified protein.  
These results led to the conclusion that the negative charges on MDA-BSA are at least 
partially responsible for FH19-20 binding to MDA-BSA. 
5.1.5 FH19-20 BINDS ONLY TO AN ABUNDANCE OF MDA ADDUCTS 
The weaker affinity of FH19-20 for A-BSA compared to MDA-BSA suggested that FH19-
20 might interact with the MDA adducts as well. To this end, hexyl-MDHDC with an 
isolated MDHDC adduct was synthesized. Whereas this compound was able to inhibit 
binding of the anti-MDHDC antibody to MDA-BSA at very low concentrations, no effect 
on FH19-20 binding could be observed on adding increasing concentrations of hexyl-
MDHDC (SI/Fig. 6A).  
Next we modified peptides containing 1, 3, or 5 lysines with MDA and confirmed the 
presence of MDHDC in them (SI/Fig. 6B). As with the isolated MDHDC adduct, the MDA 
modified peptides showed strong affinity for the anti-MDHDC antibody, but did not 
interact with FH19-20 (SI/Fig. 6C). However, when polylysine with remarkably long 
chains of lysine residues was modified with MDA, binding of FH19-20 could be detected 
(SI/Fig. 7B). Moreover, whereas intact MDA-ubiquitin was able to inhibit FH19-20 
binding to MDA-BSA, MDA-ubiquitin proteolyzed to short peptides could not interfere 
with the interaction (SI/Fig. 9D). The reason was not digestion-induced damage to 
MDA adducts, since proteolysis did not affect the fluorescence or the anti-MDHDC 
antibody interactions of MDA-ubiquitin (SI/Fig. 9B, C). 
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All in all, it was concluded that FH19-20 binds also to MDA adducts, but a somewhat 
larger cluster of adducts is necessary for the interaction to occur. 
 
5.1.6 FH19-20 BINDING CORRELATES WITH THE DEGREE OF MDA 
MODIFICATION OF BSA 
Due to the explosion hazard related to the chemical determination of the degree of 
MDA modification, we needed to contend ourselves to a relative estimate only. As MDA 
modification removed positive charges from BSA, the modified proteins were expected 
to show enhanced mobility in native PAGE. Indeed, when the concentration of MDA 
used in modification was gradually increased, the mobility of MDA-BSA was similarly 
enhanced (Fig. 28A). Further, when binding of FH19-20 was studied, increased affinity 
was observed with increasing degree of modification (Fig. 28B). On the contrary, 
binding of anti-MDHDC antibody was not affected by the degree of MDA modification 
(Fig. 28C). 
 
 
Figure 28. The degree of modification of BSA correlates with the affinity of FH19-20 for the 
modified protein. (A) When BSA was modified with increasing concentrations of MDA, mobility of 
BSA in native PAGE increased. (B) The more MDA that was used in BSA modification, the more 
FH19-20 bound to the MDA-modified protein. (C) The degree of MDA modification had no effect 
on binding of anti-MDHDC antibody to MDA-BSA. 
 
5.1.7 FH6-8 BEHAVES DIFFERENTLY FROM FH19-20 IN BINDING TO 
MDA-MODIFIED TARGETS 
Binding of FH6-8 to MDA-modified targets was analyzed along with FH19-20. Similar 
to FH19-20, on FH6-8, the binding site for MDA-BSA was shown to overlap with those 
for heparin and DNA (SI/Fig. 10A, B). Further, also FH6-8 was observed to interact with 
MDA modified polylysine but not with the isolated MDHDC in hexyl-MDHDC (SI/Fig. 
10C, D). In contrast to FH19-20, increasing the ionic strength of the buffer had only a 
moderate inhibitory effect on FH6-8 binding to MDA-BSA (SI/Fig. 10E). Moreover, 
FH6-8 was not observed to bind to A-BSA (SI/Fig. 10F), but a significant interaction 
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with MDA modified peptides containing 3 and 5 lysines was observed (SI/Fig. 10G). 
These results suggested that the interactions of FH6-8 with MDA adducts contained a 
hydrophobic element. As FH6-8 and FH19-20 behaved differently in the binding assays, 
conclusions drawn from results of FH19-20 are unlikely to apply for FH6-8. 
5.2 RESULTS OF STUDY II 
Previously, plasmin and plasminogen have been shown to affect complement proteins 
in the fluid phase. Study II analyzed the possible role of plasminogen in complement 
regulation on surfaces that can bind and activate plasminogen. 
5.2.1 FIBRIN DOES NOT ACTIVATE THE COMPLEMENT CASCADE 
Fibrin fibers are capable of both binding and activating plasminogen. Fibrin has also 
been claimed to activate the complement system [354, 358]. Therefore, fibrin was 
considered a suitable model with which to study the effect of plasminogen on 
complement propagation on surfaces. To this end, two different assay set-ups were 
developed. 
First, microtiter plates were coated with fibrinogen, and, in order to make it more 
fibrin-like, wells were treated with thrombin. The “fibrin” wells did not, however, lead 
to increased complement activation compared to the BSA control (SII/Fig. 1A), thus 
hampering studies on the effect of plasminogen on the process.  
The second model employed fibrin as miniature particles. Similar to coated fibrin, 
fibrin in the form of particles failed to activate the complement system in serum, as 
judged by identical C3a-production and residual hemolytic activity when compared to 
control (SII/Fig. 1C, D). Depletion of serum of most of plasminogen did not bring about 
complement activation by the fibrin particles either (SII/Fig. 1C, D).   
Since complement activation was not initiated against fibrin in either of the models 
tested, the possible role of plasminogen as a regulator of complement activation on 
fibrin could not be studied. 
5.2.2 PLASMIN-MEDIATED INHIBITION OF HEMOLYSIS IN SERUM IS 
NOT A PHYSIOLOGICAL PHENOMENON 
Plasmin (but not plasminogen) has earlier been shown to protect sensitized sheep 
erythrocytes (Es) from complement-mediated hemolysis in serum [251]. Similar to 
this, also in our assays plasmin inhibited erythrocyte lysis in highly diluted serum 
(SII/Fig. 2A). However, in both the reported and in our own assays, plasmin was used 
in huge excess compared to serum and erythrocytes. The concentration of plasminogen 
in human plasma is approximately 2 µM, allowing in theory the formation of 2 µM 
plasmin in 100 % plasma. The original publication [251] reported a need of 2 µM 
plasmin to enable significant inhibition of hemolysis in 1 % (!) serum.  
Next, plasmin concentration was fixed to a level corresponding to that of 20 % plasma 
(0.4 µM). This amount of plasmin efficiently inhibited hemolysis in 1.3 % serum, but 
when serum concentration was increased to 5 %, the inhibitory effect was practically 
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lost (SII/Fig. 2B). Thus, a 4-fold excess of plasmin (compared to the physiological 
plasmin/serum ratio) was not capable of preventing hemolysis. 
Further, the ability of two completely unrelated proteases to interfere with 
complement-mediated hemolysis was studied. Similar to plasmin, α-chymotrypsin and 
trypsin are powerful serine proteases showing efficient cleavage of proteins in general. 
When the inhibitory effect of a concentration of 1 µM of each of the three proteases was 
tested, very efficient prevention of hemolysis with all three was observed (SII/Fig. 2C).  
Finally, the erythrocyte assays necessitated plasminogen to be activated to plasmin 
exogenously. This was because erythrocytes do not bind plasminogen and thereby 
presumably cannot activate it to plasmin on their surfaces either. All in all, it was 
concluded that plasmin is not relevant for complement regulation on erythrocyte 
surfaces. 
5.2.3 PLASMINOGEN DOES NOT PROTECT ENDOTHELIAL CELLS FROM 
COMPLEMENT 
Similar to fibrin fibers, endothelial cells attract plasminogen on their surfaces, and in 
certain conditions the zymogen plasminogen is activated to the protease plasmin on 
these cells [245]. To study whether addition of plasminogen to serum could affect 
complement propagation on endothelial surfaces, a novel assay was developed. Human 
umbilical vein endothelial cells (HUVECs) were first loaded with the fluorescent 
compound calcein. Then they were sensitized with the antibody YHT53.1 [355], which 
both activates the classical pathway of the complement system and also hampers 
complement regulation by inhibiting function of the membrane complement regulator 
CD59. When plasminogen was introduced to serum, no effect on complement 
activation on HUVECs could be observed (SII/Fig. 3B). The positive control FH, on the 
other hand, inhibited complement activation significantly (SII/Fig. 3B).  
The effect of plasminogen on complement activation on HUVECs was initially studied 
by measuring complement deposition on HUVECs by flow cytometry. In these assays 
plasminogen caused a slight enhancement of deposition of C3b on cells incubated in 
serum, but had no effect on C5b-9 deposition (Fig. 29). These results were left out of 
the original publication (SII), because a positive control (for example FH) was missing.  
All in all, it was concluded that plasminogen does not inhibit complement regulation 
on endothelial cells. 
 
 
 
Figure 29. The effect of 
plasminogen on complement 
activation on HUVECs. (A) 
Addition of plasminogen to 
serum did not inhibit deposition 
of C3b on HUVECs incubated in 
serum. On the contrary, a 
slight enhancement was 
observed. (B) Deposition of 
C5b-9 was not affected. 
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5.2.4 PLASMINOGEN HAS A MINOR ROLE IN COMPLEMENT 
REGULATION ON PLATELETS 
Although the identity of the responsible receptor has not been confirmed, platelets are 
known to exhibit an exceptionally high capacity to bind plasminogen on their surfaces 
[359]. To study the possible role of plasminogen on complement regulation on 
platelets, the complement cascade needed to be activated against these cells. It has 
previously been shown that FH19-20 is capable of interfering with FH function on 
erythrocytes, leading to enhancement of complement activation on them [90]. This 
approach was chosen with platelets, and enhancement of complement activation on 
platelets by adding FH19-20 to serum was confirmed (SII/Fig. 4B). When also 
plasminogen was added to serum, a statistically significant, but a very minor inhibition 
in complement activation was observed (SII/Fig. 4C). 
In these platelet assays the negative serum control contained ethylene diamine 
tetraacetic acid (EDTA) (SII/Fig. 4B), which completely prevents complement 
activation [66]. It was later realized that, instead of (or in addition to) an EDTA-control, 
one should have had a control containing serum only. In other words, one should have 
compared complement activation on platelets in the presence of FH19-20 to 
complement activation on platelets in the absence of both FH19-20 and EDTA. This way 
it could have been confirmed that FH19-20 truly causes an enhancement in 
complement deposition. Thus, further assays were performed, and these verified the 
necessity of using an additional enhancer, like FH19-20, to enable complement 
activation in normal, uninhibited serum (Fig. 30). 
 
 
  
Figure 30. Complement system of serum does not activate 
against platelets unless it is specifically activated. Here it is 
shown that addition of FH19-20 to serum results in 
significant enhancement of complement deposition on 
platelets.  
 
 
 
5.2.5 PLASMINOGEN ADDITION INHIBITS PLATELET AGGREGATION 
IN SERUM 
An earlier report showed that exposure of washed platelets to serum causes them to 
aggregate [360]. In line with this, we observed serum to cause both activation and 
aggregation of platelets (SII/Fig. 5), and managed to track the reason down to 
thrombin. Namely, hirudin was able to prevent the activating effect of serum on 
platelets (SII/Fig. 5). When plasminogen was added to the system, a significant 
inhibition of platelet aggregation was observed (SII/Fig. 5B). Plasminogen did not, 
however, affect platelet activation (SII/Fig. 5B). Complement attack on platelet 
surfaces did not cause platelet activation either (SII/Fig. 6). 
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5.3 RESULTS OF STUDY III 
Sialic acid has long been considered important for FH function on erythrocyte surfaces. 
Recently, strong support for the interaction between FH and sialic acid was presented 
in the form of a co-crystal structure [58]. On endothelial cells, however, FH binding is 
generally attributed to glycosaminoglycans like heparan sulfate, although functional 
proof for this is lacking.  As sialic acid is an abundant constituent of the glycocalyx on 
endothelial cells as well, we set out to study whether sialic acid could be important for 
FH function on endothelial cells. 
  
5.3.1 MUTATIONS IMPAIR THE ABILITY OF FH19-20 TO ANTAGONIZE 
FH FUNCTION ON ERYTHROCYTES 
The C-terminus of FH is key in FH recognition of self surfaces [47, 48]. Addition of the 
C-terminal fragment FH19-20 to serum prevents the full length regulator FH from 
binding to erythrocytes and from protecting them from serum complement attack, 
thereby leading to hemolysis [90]. Mutations in FH19-20 have been shown to 
negatively affect its ability to compete with FH in binding to erythrocytes [90].  
We compared the abilities of mutant and wt FH19-20 fragments to antagonize FH 
function on serum-incubated sheep and human erythrocytes. In line with an earlier 
report [90], the mutations L1189R and E1198A were observed to be detrimental for 
FH19-20 function, whereas the mutation T1184R had only a minor effect (SIII/Fig. 2). 
The failure of FH19-20 mutants L1189R and E1198A to compete with FH was not due 
to protein misfolding, as all FH19-20 mutants efficiently prevented FH from binding to 
C3b-coated beads (SIII/Fig. 3). These results indicate that the residues L1189 and 
E1198 are important for FH function on sialic acid-bearing erythrocyte surfaces. 
 
5.3.2 SIALIC ACID IS IMPORTANT FOR BINDING OF FH TO C3b-
BEARING ERYTHROCYTES 
The binding of FH to sialic acid is very weak [58], and has been shown only in a buffer 
of 1/10 physiological strength [81]. We studied this interaction with the microscale 
thermophoresis (MST) technique. As for the sialic acid containing compound, 3’sialyl 
lactose was chosen since it has previously been shown to interact with FH19-20 in a 
crystal [58]. But even though 3’sialyl lactose concentrations of up to 50 mM were used, 
no interaction with FH could be observed (SIII/Fig. 4B). For the positive control MAL 
II, a dissociation constant of 1.1 mM could be determined (SIII/Fig. 4A). These results 
explain the lack of publications describing FH19-20 binding to sialic acid-bearing 
surfaces in physiological buffers. 
Even though the affinity of sialic acid for FH is too weak on its own to be detected, sialic 
acid nevertheless enhances FH binding to surface-deposited C3b significantly [49, 50, 
73]. Thus, binding of FH to sialic acid can be studied in the context of surface-bound 
C3b. To this end, we produced C3b-bearing sheep erythrocytes (SIII/Fig. 4C). When the 
effect of mutations on the ability of FH19-20 to inhibit FH binding to EsC3b was studied, 
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we observed the mutations L1189R and E1198A to impair FH19-20 function, whereas 
T1184R was without effect (SIII/Fig. 4G). A further dose-response experiment 
revealed the differences between wt and mutant FH19-20 fragments more clearly 
(SIII/Fig. 4H). Several control mutants were included in the experiment, and for 
example the mutation R1215Q, which has been associated with particularly severe 
clinical outcome, was observed to have a detrimental effect on FH19-20 function 
(SIII/Fig. 4H). These results are very similar to earlier data on FH19-20 function on 
erythrocytes with C3b deposition. 
To test for the importance of sialic acid in FH binding to EsC3b, sialic acid was removed 
from the cells (SIII/Fig. 4D). The sialidase treatment was given for erythrocytes only 
after deposition of C3b to ensure equal numbers of C3b-molecules on EsC3b with and 
without sialic acid (SIII/Fig. 4E). When binding of FH was analyzed, significantly less 
FH was observed to interact with EsC3b devoid of sialic acid (SIII/Fig. 4F), as expected 
on the basis of previous publications [49, 50]. Moreover, removal of sialic acid affected 
the relative affinities of FH19-20 fragments for EsC3b. Namely, on untreated EsC3b the 
wt FH19-20 significantly more efficiently competed with full length FH in binding to 
the cells, but on sialidase-treated EsC3b the wt and mutant fragments displayed 
identical ability to antagonize FH interactions with the cells (SIII/Fig. 4G, 4I). 
All in all, these results show that FH interacts simultaneously with C3b and sialic acid 
on erythrocyte surfaces and that sialic acid is critical in the interaction. 
 
5.3.3 SIALIC ACID IS INVOLVED IN FH BINDING TO C3b-BEARING 
ENDOTHELIAL CELLS 
Earlier published and our new data strongly supported the role of sialic acid in FH 
function on erythrocytes. Similar to these cells, the glycocalyx of endothelial cells is rich 
in sialic acid [361]. Thus it was hypothesized that this carbohydrate could be important 
for complement regulation on endothelium as well.  
To study the role of sialic acid in FH interactions with endothelial cells, C3b was 
deposited on HUVECs (SIII/Fig. 5A). When the sialic acid-binding lectin MAL II was 
used as a competitor, dose-dependent inhibition of FH binding to the C3b-dearing cells 
was observed (SIII/Fig. 5B). Similar to experiments with EsC3b, wt FH19-20 efficiently 
inhibited FH binding to C3b-bearing HUVECs (SIII/Fig. 5D). Also the mutant data 
paralleled EsC3b results (SIII/Fig. 5D): the mutation T1184R had no effect on the 
ability of FH19-20 to compete with FH19-20 binding to C3b-bearing HUVECs, whereas 
the mutations L1189R and E1198A proved to be harmful. Further, the experiments 
were repeated with human glomerular endothelial cells, and the results paralleled 
those of HUVECs (SIII/Fig. 5E). Finally, the ability of FH6-8 to antagonize FH binding to 
endothelial cells was studied. FH6-8 was found incapable of interfering with FH 
binding to C3b-bearing HUVECs (SIII/Fig. 5C). 
Taken together, the very similar binding patterns of FH19-20 mutants to C3b-bearing 
erythrocytes and endothelial cells suggests that FH interacts with identical targets on 
these different cells. 
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5.3.4 FH FUNCTION ON ENDOTHELIAL CELLS NECESSITATES THE 
PRESENCE OF SIALIC ACID ON THEM 
To study the role of sialic acid in FH function on endothelial cells, we developed an 
assay that measures insertion of C5b-9 complexes in cell membranes as a function of 
calcein released from cells under complement attack (please see the Materials and 
methods for details). In this assay, complement activation on endothelial cells is 
initiated with an anti-CD59 antibody. 
When working with the calcein-release assay, a minimal amount of anti-CD59 was 
used, which caused only a minor activation of complement on HUVECs (SIII/Fig. 6C). 
This was because of actual interest was to test for the ability of FH19-20 to prevent FH 
from protecting the HUVECs. This was detected as an enhancement of calcein release 
from anti-CD59-sensitized cells due to addition of FH19-20 to the system (SIII/Fig. 6C). 
When a comparison between the mutant and wt FH19-20 fragments was performed, a 
familiar pattern was observed: the mutations L1189R and E1198A proved harmful for 
the ability of FH19-20 to enhance complement activation on HUVECs, whereas T1184R 
had no significant effect (SIII/Fig. 6D). 
When sialic acid was removed from HUVECs (SIII/Fig. 6B), complement activation was 
increased (SIII/Fig. 5C). This suggested impairment in complement regulation by FH, 
but most likely the natural antibody-mediated complement activation was also 
involved. Namely, sialidase treatment of human cells leads to exposure of terminal 
galactose residues which are antigenic and therefore capable of initiating complement 
through the classical pathway [60, 61]. This complication was resolved by accepting 
the contribution of natural antibodies to complement activation on sialidase-treated 
HUVECs, and on this basis, comparing the additional complement activation-enhancing 
effects of various FH19-20 fragments. Unlike with untreated HUVECs, on sialidase-
treated HUVECs none of the FH19-20 fragments was able to interfere with FH function 
(SIII/Fig. 6E, G). This was not due to there being no further calcein to be released, since 
only a level of 60% of maximum was reached in the assay. 
To get further support for the role of sialic acid in FH regulation on endothelial cells, 
another set of functional assays was performed. Here FH19-20 was added to serum to 
antagonize FH-mediated complement regulation on HUVECs, and complement 
propagation was determined by measuring C3b deposition. Similar to earlier results, 
the mutations L1189R and E1198A were observed to abolish FH19-20 function, 
whereas T1184R had no effect (SIII/Fig. 6F). Several control mutants were included in 
these experiments, revealing the mutations W1183L, R1182A and R1215Q to be 
detrimental for FH19-20 function, but showing the mutation W1157L to be 
insignificant (SIII/Fig. 6F). When sialic acid was removed, the difference between all 
the FH19-20 fragments disappeared (SIII/Fig. 6G). 
All in all, these results are in favor of an important role of sialic acid in FH-mediated 
complement regulation on endothelial cells.  
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5.3.5 SIALIC ACID IS IMPORTANT FOR FH-MEDIATED COMPLEMENT 
REGULATION ON PLATELETS 
The as yet unknown role of sialic acid in complement regulation on platelets was 
studied using washed human platelets which had been either treated or not with 
sialidase (SIII/Fig. 7A). The sialidase treatment itself was observed to activate the 
platelets slightly (SIII/Fig. 7B). However, as expected on the basis of earlier reports (SII 
and [360]), exposure of platelets to serum caused a further increase in their activation 
level. Importantly, in serum, the untreated and sialidase-treated platelets reached the 
same level of activation (SIII/Fig. 7B). This ruled out the possibility that differences in 
P-selectin levels could differentially affect complement activation in our system, as 
reported earlier for chinese hamster ovary cells [362]. 
For the actual complement activation experiments, we chose to perform C3b-
deposition assays similar to those developed for HUVECs. It was observed that addition 
of wt FH19-20 to serum augments C3b deposition on platelets (SIII/Fig. 7C). The 
mutation T1184R did not affect FH19-20 function significantly, whereas L1189R and 
E1198A proved to be harmful (SIII/Fig. 7D). Similar to assays with endothelial cells, no 
differences between the wt and mutant FH19-20 fragments could be observed in the 
absence of sialic acid (SIII/Fig. 7E). Further, control mutant data of experiments with 
platelets (SIII/Figs. 7F, 7G) paralleled earlier results obtained with other types of cells. 
Taken together, these results show that, similar to erythrocytes and endothelial cells, 
platelet protection from complement also necessitates sialic acid. 
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6 DISCUSSION 
Atypical hemolytic uremic syndrome (aHUS) is a rare systemic disease characterized 
by hemolysis, thrombocytopenia and renal impairment [363]. In 40-70% of aHUS 
patients one or several abnormalities in complement genes can be detected, and in 6-
10% of cases the presence of anti-FH autoantibodies can be shown [282]. The 
mutations and antibodies are generally accepted to result in reduced regulation of the 
complement cascade on self cells [364]. Despite decades of research, the detailed 
mechanisms underlying aHUS pathogenesis remain incompletely understood.  
The work described is this thesis focused on malfunction of complement regulation on 
surfaces. Erythrocytes, endothelial cells, and platelets were chosen as the models, 
because these three types of cells are all adversely affected in aHUS [363]. Whereas the 
role of complement in erythrocyte lysis in aHUS remains uncertain, abnormal 
activation of the cascade on endothelial cells especially lining the glomerular 
microvasculature [363] and platelets [365] is known to be involved. 
The most frequently mutated gene in aHUS is that of the regulator FH [282, 286-288]. 
The mutations cluster in the two most C-terminal domains (FH19-20) [290-292], and 
are generally accepted to cause excessive complement activity by preventing FH from 
properly protecting cells from complement attack. To perform its regulatory function, 
FH needs to recognize a specific self marker on cell surfaces. On endothelial cells, this 
marker is generally considered to be heparan sulfate [51].  However, data on binding 
of FH19-20 fragments carrying aHUS-associated mutations to heparin or endothelial 
cells does not explain malfunction of FH mutants. Namely, whereas some mutations 
decrease FH19-20 binding to heparin and endothelial cells, others cause an increase in 
affinity [90, 138]. It is very difficult to envision how these opposing deviations from 
normal FH binding could lead to the common outcome of reduced FH function. Thus, it 
was concluded that a marker other than heparan sulfate necessarily exists on 
endothelial cells. As sialic acid mediates FH recognition on erythrocytes [49, 50], it was 
hypothesized that this sugar could be the marker of self on endothelial cells as well. 
MDA adducts, which were recently reported to interact with FH19-20 [143], were 
considered another plausible candidate for the marker of self.  It was then investigated, 
whether disturbed interactions with either sialic acid or MDA adducts could explain 
malfunction of FH molecules carrying mutations associated with aHUS. 
Considering that aHUS is a thrombotic microangiopathy, it is not surprising that, 
besides complement factors, several coagulation and fibrinolytic proteins have become 
associated with the disease [229, 344-347]. Recently, several aHUS patients with a 
reduced level of the fibrinolytic protein plasminogen were described, although 
impaired fibrinolysis was suggested to explain the link [344]. Both the zymogen 
plasminogen but especially its active protease form plasmin are known for their 
complement-inhibiting activities in fluid phase [251]. In this work, the role of 
plasminogen in complement regulation on self cell surfaces was studied. 
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6.1 MDA ADDUCTS AND aHUS PATHOGENESIS  
Several attributes are in favor of formation of MDA in the thrombotic microangiopathy 
aHUS. For example, during platelet activation, MDA is produced in equimolar amounts 
compared to thromboxane A2 [145]. Further, intravascular hemolysis releases 
hemoglobin into plasma, and redox-active iron is capable of both initiation and 
catalysis of lipid peroxidation [366, 367], the other natural source of MDA [144, 146]. 
Moreover, inflammation often involves an acidic environment, which drives the 
equilibrium between the two isomeric forms of MDA towards the more reactive β-
hydroxyacrolein [144]. All in all, it is evident that at least some MDA is generated in 
aHUS.  
6.1.1 DOES MDA MODIFICATION OCCUR IN aHUS? 
Although MDA formation in aHUS is plausible, the presence of MDA adducts on 
damaged cells in patients with the syndrome should have been verified before rushing 
into experiments with the disease-associated FH mutants and MDA-modified proteins. 
This, however, would not have been a straightforward task. For example, the chemical 
analyzes for MDA adducts have been developed for soluble proteins, not for cells or 
tissue sections. Furthermore, the method of Habeeb [152], for example, is not specific 
for MDA adducts, but measures lysine modification in general. Fluorescence detection, 
on the other hand, shows the presence of the specific MDHDC structures [154, 155], 
but tells nothing about the concentration of the (presumably dominating) more simple 
adducts. The same is true of many anti-MDA-adduct antibodies: they detect only the 
complex MDHDC structures [368]. For other antibodies (or antisera), the specificity for 
MDA-adducts is unclear and / or questionable [151, 369]. Thus, there is a need for 
specific anti-MDA-adduct antibodies that recognize the less complex MDA adducts. 
With these, the question of the presence of MDA epitopes in aHUS patient tissue 
samples could be answered. 
6.1.2 IS MDA MODIFICATION IN VIVO EXTENSIVE ENOUGH TO 
ENABLE FH19-20 BINDING? 
Even if the presence of MDA adducts would be verified in aHUS, their role in disease 
pathogenesis would still be in doubt. Namely, it was observed that an abundance of 
closely spaced MDA adducts is necessary for the interaction between FH19-20 and 
MDA adducts to occur (SI/Figs. 6, 9). It is questionable, whether enough MDA can be 
liberated in vivo to allow formation of the high density of MDA adducts necessary for 
FH19-20 binding. Several arguments against extensive in vivo modification of cell 
surface proteins by MDA can be presented. First, even if a generous burst of MDA was 
liberated to blood, the highly concentrated plasma proteins (most notably albumin 
with a reference range of 35-50 mg/ml) would presumably react with it and thereby 
markedly reduce the level of MDA available for modification of cell surface proteins. 
Second, unlike the long-lived deposits in the macula of eye [370], endothelium is 
unlikely to show accumulation of MDA epitopes due to the renewable nature of these 
cells. Third, besides MDA, several other (often more reactive) compounds are released 
during oxidative biological processes, and these, too, cause modification of proteins 
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[144]. Although for example 4-hydroxynonenal reacts with different amino acid side 
chains than MDA, the presence of 4-hydroxynonenal adducts in a protein could 
interfere with further modification by MDA. All in all, several aspects related to MDA 
modification cast serious doubt on sufficient MDA modification of cell surface proteins 
to allow FH19-20 binding. However, the involvement of MDA adducts in aHUS cannot 
be excluded on the basis of current data. 
 
6.1.3 DO MDA ADDUCTS PROVIDE SURFACES WITH PROTECTION 
FROM COMPLEMENT ACTIVATION? 
Perhaps the most relevant question regarding FH interactions with MDA adducts is 
whether the latter actually bring about any protection from complement attack. The 
authors originally describing the interaction between FH and MDA adducts claimed 
that MDA epitopes recruit FH onto surfaces to halt complement propagation [143]. 
However, the data presented in the article did not justify such a statement. For 
example, co-localization of FH with MDA adducts on human macula or the ability of 
MDA-BSA to prevent FH from binding to presumed MDA-adducts on apoptotic blebs 
merely suggest that FH binds MDA adducts. Similarly, the observation of FH cofactor 
activity in MDA-BSA-coated wells (incubated first with FH and then with C3b and FI) 
only shows that FH is retained in the wells during washes, or, in other words, binds 
MDA-BSA.  
To prove the speculated enhancement of FH-mediated complement regulation by 
expression of MDA adducts on a surface, proper functional data is required. It should 
be shown, for example, that the appearance of MDA adducts on C3b-bearing surfaces 
truly enhances inactivation of the deposited C3b. These experiments are, however, 
expected to be complicated by the presence of natural anti-MDA-adduct antibodies that 
circulate in the vasculature [164-174]. In addition to enhancing complement initiation 
through the classical pathway, the anti-MDA-adduct antibodies could impair FH 
binding to surface-deposited C3b. FH and natural antibodies were reported to bind 
MDA-BSA simultaneously [143], but since the relative affinities were not studied, 
predictions on the effect of natural antibodies on FH function are difficult to be made. 
All in all, it remains to be investigated whether MDA adducts truly affect complement 
regulation on surfaces, and if so, what steps of the cascade are influenced and how. 
 
6.2 SIALIC ACID AND FH-MEDIATED 
COMPLEMENT REGULATION  
The effect of aHUS-associated mutations on the interactions of FH19-20 with its 
binding partners has been studied by several authors [90, 138]. The aim has 
presumably been to verify impaired affinity of each mutant FH19-20 to either C3b or 
heparin, which would then explain malfunction of full length FH molecules with the 
same mutations. It has turned out that some aHUS-associated mutations, like R1182A 
and R1210A, indeed impair binding of FH19-20 to C3b, heparin, and endothelial cells 
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[138]. However, some mutations, including T1184R and L1189R, surprisingly increase 
FH19-20 affinity to all three binding partners [90, 138]. Since it was difficult to explain 
how better binding of FH to heparin, cells, and C3b could lead to worse complement 
regulation, it was concluded that some alternative target necessarily exists. 
6.2.1 SIALIC ACID IS CRITICAL FOR FH-MEDIATED COMPLEMENT 
REGULATION ALSO ON ENDOTHELIAL CELLS AND PLATELETS 
In contrast to interactions with heparin, endothelial cells, and C3b, direct binding of 
sialic acid to FH is too weak to be measured in a physiological buffer (SIII/Fig. 4B and 
[81]). Sialic acid does, however, enhance FH binding to C3b [49, 50], and thus FH 
interactions with sialic acid can be investigated in the context of C3b. Sheep 
erythrocyte surfaces (Es) are rich in sialic acid, and thus C3b deposited on these cells 
(EsC3b) provides a suitable model to study FH binding. Interestingly, it has been shown 
that regardless of whether a FH19-20 mutant displays decreased or increased affinity 
for heparin, endothelial cells, or C3b, every FH19-20 fragment carrying an aHUS-
mutation shows reduced binding to EsC3b [90]. Functional data of hemolysis assays 
parallels this binding assay result: mutations linked to aHUS impair the ability of FH19-
20 to antagonize FH regulation on Es [90]. These results suggested that FH regulation 
on erythrocytes presumably involves interactions with both sialic acid and C3b. 
Similar to erythrocytes, both endothelial cells and platelets also express an abundance 
of sialic acid in their surface glycocalyx layers [361, 371]. Since impaired FH19-20 
mutant binding to neither heparin nor endothelial cells was capable of explaining 
malfunction of FH carrying aHUS-associated mutations, it was asked whether 
disturbed interactions with sialic acid in the context of C3b could be the reason for 
impaired mutant FH function also on endothelial cells and platelets. To answer this 
question, several binding and functional experiments with erythrocytes, endothelial 
cells, and platelets were performed. With all types of cells studied, the pattern of 
inhibition of FH function by the FH19-20 fragments was identical: The mutations 
R1182A, W1183L, L1189R, E1198A, and R1215Q impaired FH19-20 ability to 
antagonize FH function, whereas the mutations W1157L, T1184R, and K1186A had (at 
most) a minor effect on FH19-20 function (SIII/Figs. 2, 4-7). In addition to the pattern 
of FH inhibition being very similar with all three types of cells studied here, it also 
paralleled with earlier data on FH19-20 mutant binding to erythrocytes [90]. These 
results suggested that FH regulation on endothelial cells and platelets involves the 
same self surface marker as is necessary on erythrocytes, that is, sialic acid.  
The role of sialic acid in FH-mediated complement regulation on endothelial cells and 
platelets was further corroborated by our sialidase experiments. Namely, removal of 
sialic acid from cell surfaces impaired the ability of FH19-20 to antagonize FH function 
on cells (SIII/Fig. 4, 6, 7). Very convincing was also the parallelism between our new 
experimental data and earlier structural predictions [58]. Based on the crystal 
structure of FH19-20 in complex with sialic acid and C3d, the mutations W1183L and 
R1215Q were earlier predicted to remove the two most important interactions of 
FH19-20 with sialic acid [58]. In our assays, these mutations completely abolished 
FH19-20 function (SIII/Figs. 4-7). The residues L1189, R1182 and E1198, on the other 
hand, display less direct interactions with the sialic acid in the ternary complex [58], 
explaining the much milder impairment of FH19-20 function due to mutation of these 
residues (SIII/Figs. 2, 4-7). Finally, T1184, K1186 and W1157 do not interact with the 
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sialic acid [58], and indeed very little effect on FH antagonism was observed when 
T1184R, K1186A or W1157L were used in place of the wt FH19-20 (SIII/Figs. 2, 4-7). 
During revision of the last manuscript (SIII), a report on FH19-20 interactions with 
mouse glomerular cells was published [372]. Functional complement activation 
experiments similar to ours had been performed, and the results paralleled our data. 
For example, the mutations E1198A and R1215Q were shown to prevent FH19-20 from 
antagonizing FH function on endothelial cells, leading to less C3b deposition on cells 
incubated in serum. The role of sialic acid was not studied. Instead, experiments with 
heparinases were employed, and impaired binding of FH and FH19-20 to cells after 
heparan sulfate removal was reported. However, the effect of heparinase treatment on 
mutant FH19-20 binding was not reported. Neither was it studied whether removal of 
heparan sulfate from cells would have an effect on FH function (as removal of sialic 
acid did in our assays, SIII/Figs. 4, 6, 7). Instead of erroneous heparan sulfate binding, 
disturbed sialic acid recognition best explains the functional data obtained from these 
recent mouse cell experiments.   
Taken together, unlike defective interactions with heparin or C3b, the variously 
impaired ability of different FH19-20 mutants to simultaneously recognize both sialic 
acid and C3b on cell surface can explain the observed pattern with which the mutants 
antagonize FH function. Impaired recognition of sialic acid in the context of C3b 
provides a general and unifying explanation for loss of complement regulation in aHUS 
featuring different C-terminal mutations in FH. 
6.2.2 HOW SPECIFIC ARE THE INTERACTIONS BETWEEN FH19-20 
AND NEGATIVELY CHARGED POLYANIONS? 
The finding of sialic acid to be critical for FH function on multiple different types of cells 
raised the question of the significance and specificity of the interactions of FH19-20 
with the polyanions heparin and DNA. The GAG heparin is rich in carboxyl and sulfate 
groups, both of which are deprotonated (i.e. carry negative charge) at physiological pH 
[101]. Of all natural biomolecules known, heparin shows the highest density of 
negative charge [373]. The sulfates presumably mediate FH19-20 binding to heparin, 
since removal of variously linked sulfate groups from heparin either reduces or 
completely abolishes FH19-20 binding [51]. Similar to heparin, DNA is a highly charged 
polyanion showing affinity for FH19-20 [374]. The negative charge of DNA is due to its 
backbone phosphates. Not much data is available on FH interactions with DNA, except 
for the puzzling observation of increased binding of FH (and of anti-DNA antibody) to 
apoptotic cells after a treatment with DNAse [374].  
Considering that MDA adducts are neutral structures, it was first thought odd that 
FH19-20 should interact with MDA-BSA using an overlapping site with those of the 
polyanions heparin and DNA (SI/Fig. 4). Equally surprising was the clear dependency 
of FH19-20 interactions with MDA-BSA on the degree of positive charge of the FH19-
20 fragment (SI/Fig. 3). Further investigation on the issue revealed that MDA 
modification increases the negative charge of the protein under modification by 
removing positive charges of lysines [144]. It is presumably the negative charges on 
the MDA-modified protein that interact with FH19-20.  
If negative charges of MDA-BSA dominate its binding to FH19-20, what should be 
thought of the specificity of the interactions of FH19-20 with negatively charged 
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compounds in general? Even though heparin, DNA and MDA-BSA all carry negative 
charges, they differ tremendously at atomic level. How could a single site on FH19-20 
be capable of forming specific bonds with all these three ligands? Furthermore, how do 
we explain the additional observation of FH19-20 binding to the negatively charged 
unmodified pepsin (pI 3.2; ExPASy Bioinformatics Resource Portal). Or binding of full 
length bovine FH to the negatively charged sulfo-tyrosine resin [375]? Instead of 
specific interactions, the answer could be unspecific attraction due to opposite charges. 
Namely, in contrast to all the above mentioned ligands, FH19-20 is a highly positively 
charged macromolecule with a pI of 9.1 (estimated value; ExPASy Bioinformatics 
Resource Portal). Thus it is proposed that FH19-20 interactions with negatively 
charged polyanions involve mainly unspecific charge attractions. 
Even though presumably unspecific, binding of the C-terminus of FH to heparin (or 
heparan sulfate) might still be significant. Whereas sialic acid is necessary for proper 
recognition of surface deposited C3b, heparan sulfate could be important for attracting 
FH closer to the cell surface. 
6.2.3 WHY DOES FHR1 NOT PREVENT FH FUNCTION IN VIVO? 
Confirmation of the necessity of sialic acid for FH regulatory function on cells also 
answers the puzzling question of coexistence of factor H-related protein 1 (FHR1) 
along with FH in serum. FHR1 lacks the N-terminus of FH necessary for cofactor and 
decay-accelerating activities [376], but the two C-terminal domains of FHR1 and FH 
differ from each other only by two residues [377]. Compared to FH, FHR1 contains the 
amino acid changes S1191L and V1197A. Studies on the effect of the double mutation 
S1191L/V1197A on FH19-20 function have reported either decreased [377] or 
increased [90] binding to C3b. The double mutation has no effect on interactions with 
heparin [90, 377, 378], and therefore FHR1 can compete with FH for binding to this 
GAG [379]. FHR1 also binds to endothelial cells and co-localizes with FH on them [379]. 
The plasma concentration of FHR1 (2 µM) [379] is very similar to the level of FH (1-4 
µM) [380]. So why, then, does FHR1 not seem to prevent FH from protecting self 
surfaces from complement activation in vivo? 
Even though the double mutation S1191L/V1197A does not affect FHR1 binding to C3b 
[90, 377], heparin [90, 377, 378], or endothelial cells [379], it most likely prevents 
FHR1 from recognizing sialic acid on surfaces. The recent co-crystal structure between 
FH19-20, sialic acid and the C3d-part of C3b allows the prediction that the mutations 
S1191L and V1197A would cause a clash with the sialic acid glycerol side chain, 
thereby excluding FHR1 interactions with sialic acid [58]. Support for this was 
provided earlier by showing that the double mutation S1191L/V1197A markedly 
impairs the ability of FH19-20 to antagonize FH function on sialic acid-bearing EsC3b 
[90]. Data on the FHR1/FH hybrid protein (observed in some patients with aHUS [308, 
309]) further corroborate the interpretation. Unlike FHR1, the FHR1/FH hybrid 
protein functions as an antagonist of FH, causing increased complement activation on 
cells in serum [308]. This is presumably due to the following: the C-terminal domains 
of FHR1/FH originate from FH, and therefore direct the hybrid protein onto cell 
surface. As the N-terminal FHR1-domains of the hybrid lack complement regulatory 
function, no inhibition of C3b occurs. By binding to cells under complement attack, 
FHR1/FH hybrid prevents normal FH from controlling the complement cascade on 
cells [308].  
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Taken together, the co-localization of FHR1 with FH on endothelial cells in the absence 
of C3b is probably best explained by binding of FHR1 and FH to cell surface GAGs. 
However, due to the double amino acid difference (S1191L/V1197A), FHR1 is unable 
to form a ternary complex with sialic acid and C3b during complement attack. 
Therefore FHR1 does not compete with FH binding to C3b deposited on sialic acid-
bearing cells, and has no effect on FH-mediated regulation of the complement cascade. 
6.2.4 IS REDUCED SIALIC ACID CONCENTRATION ON CELL SURFACES 
INVOLVED IN TRIGGERING OF aHUS? 
Mutations in FH predispose to aHUS, but are not sufficient to cause the disease [282]. 
An additional triggering event, like an infection, a drug, or pregnancy, is needed for 
disease onset, but the molecular mechanisms involved are poorly understood. This 
makes sialic acid – or rather some reduction in the expression of this sugar on cell 
surfaces – highly interesting in the context of the syndrome. 
An infection with the sialidase-producing bacterium Streptococcus pneumoniae is 
known to trigger aHUS in some cases. The sialidase-activity of this microorganism is 
generally accepted to trigger disease through exposure of complement activating 
Thomson-Friedenreich antigens [381]. Alternatively, the reduction in cell surface sialic 
acid during infection could lead to impaired recognition of self cells by the complement 
regulator FH. Considering the very high abundance of sialic acid in cell surface 
glycocalyx [55], it is questionable, however, whether the presumably limited amount 
of bacterial sialidase released during infection could remove enough sialic acid from 
cells to cause significant impairment in FH function.  
In addition to bacterial sialidases, a trigger could affect the human counterparts. In 
other words, a trigger could, for example, cause upregulation of production of 
endogenous sialidases. Increased expression of sialidases has been reported for 
example in membranous glomerulopathy [382].  
Reduced availability of sialic acid on cells could also be due to a trigger causing general 
adverse effects on the glycocalyx. For example, bacterial lipopolysaccharide has been 
shown to lower the amount of sialic acid in glomerular endothelial surface layer by 30 
% [383], and aHUS is known to be triggered by bacterial infections in some cases [282]. 
A trigger could also hamper FH-mediated recognition of cells by bringing structural 
changes on cell surface sialic acid. The most prevalent natural modification of sialic acid 
is acetylation of the OH-group in carbon-9 [384]. This modification has several 
functional implications, in particular in the immune system [385]. At normal 
conditions, rat kidney glomeruli, for example, show significant expression of 9-O-
acetylated sialic acid [386]. Considering FH function, 9-O-acetylation of sialic acid is 
detrimental. The importance of the presence of an OH-group in carbon-9 for efficient 
complement regulation was observed already long ago [84-89], but only recent 
structural data [58] allowed explanation of these observations. The additional acetyl 
group in sialic acid carbon-9 cannot be accommodated in the hydrophobic pocket in 
FH19-20 into which the glycerol chain of unmodified sialic acid fits. Thus, 9-O-
acetylation prevents FH19-20 from binding to sialic acid [58]. Thus, an aHUS trigger 
could tip the normal balance between unmodified and 9-O-acetylated sialic acid 
markedly towards increased acetylation, resulting in less FH binding.    
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All in all, it will be interesting to see, whether some triggers of aHUS can hamper FH-
mediated complement regulation by bringing about a reduction in cell surface sialic 
acid and thereby participate in setting the disease off. 
6.3 PLASMINOGEN AND COMPLEMENT 
REGULATION 
Both the zymogen plasminogen but especially the protease plasmin have been 
reported to display complement-inhibiting activities [251]. Much of the research has 
been performed with fluid phase components. Central to the pathogenesis of aHUS, 
however, is impaired regulation of complement activation on cell surfaces. It was 
asked, whether plasminogen or plasmin could control complement propagation on 
cells. 
6.3.1 PLASMIN-MEDIATED INHIBITION OF HEMOLYSIS IS NOT A 
PHYSIOLOGICAL PHENOMENON 
Erythrocytes do not bind plasminogen [359], and therefore are not expected to support 
conversion of plasminogen to plasmin on their surfaces either. Thus, when studying 
the role of plasmin in complement activation on erythrocytes, exogenously activated 
plasmin needs to be employed. Doing this, Barthel et al. [251] were able to show that 
plasmin inhibits complement-mediated lysis of sensitized sheep erythrocytes in serum. 
Also in our hands, plasmin was observed to practically prevent complement-mediated 
hemolysis (SII/Fig. 2A). However, the phenomenon was observed only in highly 
diluted serum, with the protective effect of plasmin disappearing with increasing 
serum concentration (SII/Fig. 2B). This was presumably due to two reasons. First, the 
free plasmin added to serum was not protected from natural protease inhibitors by 
surface attachment, but instead was vulnerable to inactivation by α2-antiplasmin 
[246]. Second, plasmin is known to cleave several serum proteins [187, 188, 220, 251, 
253, 256-260]. Adding more serum to the system probably overwhelmed the 
proteolytic capacity of plasmin. Thus, it was concluded that the observed inhibition of 
hemolysis by plasmin is best interpreted as to result from an overload of exogenously 
activated protease and not as a physiologically relevant phenomenon. 
6.3.2 WHY DOES FIBRIN NOT SUPPORT COMPLEMENT 
PROPAGATION? 
The alternative pathway of complement activates spontaneously on all surfaces 
bearing OH- or NH2-groups [7]. If uninhibited, complement cascade propagation on the 
surface follows. As fibrin is an assembly of multiple polypeptide fragments, it is 
expected to support complement initiation (at least) by the alternative pathway on its 
surface.  
Two earlier reports claim that fibrin indeed activates the complement system of serum. 
What comes to the assays performed by Endo et al. [354], only a very slight increase in 
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deposition of C4b on fibrinogen was detected. Further, no mention of subtracting the 
background C4 binding was made. Shats-Tseytlina et al. [358], on the other hand, 
measured liberation of C3a in the presence of fibrin fibers, but omitted the positive 
control from their assays, making the assessment of the relevance of their results 
difficult. After all, detection of C3a can be very sensitive, and therefore proper controls 
are necessary. All in all, earlier data on complement activation on fibrin surfaces was 
not considered reliable. Thus, our failure to confirm previous findings (SII/Fig. 1) was 
not considered worrying. 
Since complement activation on fibrin was not observed (SII/Fig. 1), some means of 
regulation of the complement cascade on fibrin fibers must exist. Plasminogen (or 
plasmin), the most obvious candidate(s), are unlikely to be responsible, because 
removal of most of plasminogen from serum did not cause an enhancement of 
complement activation on fibrin particles in our assays (SII/Fig. 1). Natural fibrin 
networks are decorated with immobilized regulatory factors including α2-antiplasmin 
[247], which could affect complement function. Only fibrinogen and thrombin were 
used to prepare the fibrin surfaces in our models, but evidently some serum factors 
might have been attracted onto fibrin during incubations as well. Taken together, 
activation and regulation of complement cascade on fibrin fibers remains unresolved. 
 
6.3.3 PLASMINOGEN IS NOT IMPORTANT FOR COMPLEMENT 
REGULATION ON ENDOTHELIAL CELLS 
Endothelial injury is considered a central factor among the events that lead to 
thrombotic microangiopathy. In aHUS, damage to cells especially lining the glomerular 
microvasculature is observed [363]. Defective regulation of complement is thought to 
be involved, but the molecular details are somewhat unclear.   
Failure of plasminogen to inhibit serum complement activation on endothelial cells 
(SII/Fig. 3) was, perhaps, not that surprising. After all, plasminogen is only a zymogen. 
Barthel et al. [251] reported that plasminogen enhances FH cofactor activity in C3b 
inactivation by factor I, but the observed effect was extremely weak. Further, a negative 
protein control was missing from the described experiment [251], reducing the 
reliability of the interpretation of the results. 
Unlike plasminogen, the protease plasmin is capable of cleaving several complement 
proteins [187, 188, 220, 251, 256-260]. Besides fibrin fibers [244], plasmin is produced 
in vivo on endothelial cell surfaces, where co-localization of plasminogen and tPA (or 
receptor-bound uPA) to Annexin II-S100A10 heterotetramers allows activation of the 
zymogen [245]. Thus, it was expected that serum plasminogen would activate to 
plasmin on endothelial cells and that some effect on complement activation would be 
observed. However, the assumed activation of plasminogen to plasmin was not verified 
in Study II.  
On the contrary, it is presumable that no plasmin formation occurred in our endothelial 
cell experiments. First, and most importantly, the concentration of the necessary 
plasminogen activator tPA was probably insufficient. Namely, we used serum that has 
a reduced content of tPA compared to plasma, and the serum was generously diluted 
in the assays. Similar to plasminogen, extra tPA should perhaps have been added to 
ensure sufficient tPA for plasmin conversion. Second, the loose HUVECs used in the 
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experiments were probably not in the best possible condition. The 0.02% EDTA 
treatment used to detach HUVECs from plates (to avoid cell surface protein damage by 
trypsin) might have inflicted the cells a little, but a more serious violation was probably 
the long incubation of detached cells in PBS afterwards. It is a good question, whether 
the cells could have supported plasmin production at the point when they were used, 
even if enough plasminogen and tPA had been available. Third, even though HUVECs 
are of endothelial origin, glomerular microvascular endothelial cells might have been 
a more representative model (like in [331, 348]), especially considering our context of 
aHUS. Moreover, pre-activation of endothelial cells with, for example, TNF-α (as in 
[138, 372]) could have enhanced plasminogen conversion on their surfaces, thereby 
making assessment of the hypothesized role of plasmin in complement regulation 
easier. 
Should further experiments with plasmin and endothelial cells be performed, changing 
the complement source from serum to hirudin-plasma could be considered. This would 
not only reduce the problem of insufficient tPA, but could also prevent a false positive 
result. Namely, similar to several complement components, plasmin also cleaves 
fibrinogen [244]. Thus, fibrinogen is expected to compete with complement 
components for proteolysis by plasmin. Even though the affinity of plasmin for the 
inactivation product of C3b, i.e. iC3b, is roughly equal to that of fibrinogen [257], 
experiments with bacteria suggest that C3b itself is a poor substrate [264-269]. 
Therefore fibrinogen is expected to interfere with C3b inactivation by plasmin. Thus, 
even if plasmin-mediated complement regulation in serum could be shown, the real 
question is, whether plasmin cleaves complement components on cells in the presence 
of the highly abundant competitor fibrinogen (2-4 mg/ml [387]) of plasma.  
Taken together, plasminogen is not important for complement regulation on 
endothelial cells. The possibility of the role of plasmin in complement regulation on 
these cells remains, but is perhaps unlikely due to other plasma proteins (mainly 
fibrinogen) to be more favorable substrates for this protease. 
 
6.3.4 IS COMPLEMENT INVOLVED IN DISEASE PATHOGENESIS IN  
aHUS-PATIENTS WITH PLASMINOGEN DEFICIENCY? 
Even if future experiments would confirm both plasminogen and plasmin to be 
incapable of regulating complement in vivo, the complement system might be involved 
in the disease pathogenesis of aHUS patients with plasminogen deficiency in some 
other way. This is perhaps more likely than not, since plasminogen deficiency as the 
sole abnormality has mainly been associated with ligneous conjunctivitis [388]. 
Plasminogen deficiency alone does not seem to increase risk of thrombosis either 
[389]. 
Interestingly, three of the four aHUS patients with plasminogen deficiency were also 
reported to carry variant forms of complement genes [344]. The effect of the observed 
nucleotide changes in genes C1S, C3, C8A, and CFHR5 is as yet unknown [344], but the 
mutation R154X in C9 has been shown to cause deficiency of the respective 
complement protein [390]. Reduced availability of C9, on the other hand, is expected 
to impair C5b-9 insertion in cell plasma membranes. In one study, membrane C5b-9 
was observed to increase plasminogen binding to surface, and interactions with 
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plasminogen were mainly attributed to C9 [250]. Reduced C9 levels could lead to 
decreased plasminogen attraction onto endothelial cells during complement attack, 
especially in the context of concurrent plasminogen deficiency. 
Another aspect to consider is the effect of complement activity on fibrinolysis. 
Complement C3 has been shown to interact with both fibrinogen and fibrin [391]. C3 
is a substrate for the cross-linking enzyme transglutaminase XIIIa [392], and becomes 
incorporated within the fibrin network during clotting [391, 393, 394]. The presence 
of C3 within the clot leads to a moderate prolongation of clot lysis time [391, 393, 394], 
which is presumably related to formation of thinner fibrin fibers in the presence of C3 
[393]. Preliminary results suggest that activation of the complement system prior to 
coagulation affects fibrinolysis of the resulting fibers [358]. It remains to be studied 
whether complement activation (mainly conversion of C3 to C3b) during fibrin 
assembly has an adverse effect on later degradation of the clot. Impairment of 
fibrinolysis due to complement activation during clot formation could be one factor in 
tipping the balance towards aHUS (instead of ligneous conjunctivitis) in subjects with 
plasminogen deficiency. 
The question of complement involvement in aHUS patients with plasminogen 
deficiency could probably be answered by studying the response of these patients to 
treatment with the therapeutic anti-C5 antibody eculizumab [395]. This data was not 
available in the original report describing the patients [344]. Further inquiries were 
made by directly contacting the authors, but no information of the possible effect of 
eculizumab in aHUS patients with plasminogen deficiency could be obtained. Thus, the 
question of the role of complement in plasminogen-aHUS remains.    
6.4 COMMENTS ON MATERIALS AND METHODS 
6.4.1 SHOULD SERUM OR PLASMA BE EMPLOYED? 
In the experiments described in this thesis, serum was used as the source of functional 
complement. This is a major shortcoming, since serum is an unnatural, artificial 
product. Namely, serum is prepared by leaving a glass tube filled with blood on table 
for about 30 minutes (during which time the blood clots), followed by centrifugation 
and removal of the formed clump. Clotting removes much of the fibrinogen in the 
process of fibrin formation, but also introduces new products to the system, including 
fibrinogen cleavage fragments. There is a danger that these newly formed compounds 
have an effect on certain experiments. This was seen, for example, in Study II, where 
thrombin caused activation of platelets when these cells were exposed to serum. 
With the uncertainties related to serum, why not use plasma instead? If plasma is 
employed in experiments as such, coagulation of the samples hampers measurements. 
EDTA can be added to chelate Ca2+ to prevent coagulation, but is also inhibits the 
complement system. Low concentrations of citrate can also be used to stop coagulation, 
but even in diluted citrate buffers the complement activities are impaired to some 
extent. One inhibitor that affects only the coagulation system (by preventing thrombin 
function) is hirudin, and hirudin-plasma could be used in complement assays. In any 
case, as serum contains a fully functional complement system and is easy to obtain, it 
is no wonder that it has become a most popular tool in complement research.  
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Serum is likely a suitable source of complement (or its components) in some 
experiments. This is the case, for example, when one compares binding of different 
FH19-20 mutants to binding of full length FH of serum to some surfaces. The suitability 
of serum can, however, become questionable if complement function on cells or in 
relation to coagulation cascade propagation is studied. First, as pointed above, the 
newly formed compounds in serum can bring about unwanted side effects on various 
cells. Second, in the absence of fibrinogen, the is no proper function of the coagulation 
cascade, which is expected to impact the putative interactions between the 
complement and coagulation systems heavily. But how indeed to investigate 
complement-coagulation crosstalk  in systems involving cells and coagulation? 
 
6.4.2 CELLS DID NOT LYSE IN THE CALCEIN-RELEASE ASSAYS 
To more easily analyze complement activation on endothelial cells, a calcein-release 
assay was set up. The new method was first employed in Study II. At that time it was 
simply assumed that complement activation on endothelial cells leads to their lysis, 
liberating calcein from cells. This was because the anti-CD59 antibody that was used to 
initiate complement activation on the HUVECs also impairs function of the complement 
membrane regulator CD59. However, prompted by a reviewer’s comment during 
revision of the last manuscript (Study III), it became clear that the calcein-filled 
endothelial cells did not lyse during the experiments. Namely, no sign of the cellular 
enzyme lactate dehydrogenase could be observed in the supernatant samples (SIII/Fig. 
6A). This was true also of the samples with the highest concentrations of anti-CD59. In 
contrast to the large lactate dehydrogenase protein, the very small calcein was 
observed to be released from cells due to anti-CD59 (SIII/Fig. 6A). Thus it was 
concluded that anti-CD59 caused insertion of C5b-9 complexes within cell plasma 
membranes, allowing calcein to escape but holding lactate dehydrogenase inside. In 
other words, the new assay detected complement activation as a function of C5b-9 
insertion in cell membranes. 
Prior to us, other researches have previously made the same mistake of taking cell lysis 
by complement for granted (see for example [193, 396]). Without studying lactate 
dehydrogenase release, calcein liberation from cells has been assumed to indicate cell 
lysis. Similar to this, liberation of radioactive 51Cr from 51Cr-filled cells has been used 
as a measure of cell lysis without confirming lactate dehydrogenase release that is 
necessarily involved in cell rupture (see for example [397, 398]). 
At least in our case, however, the question of whether calcein release was truly due to 
cell lysis, or merely a measure of C5b-9 insertion in cell membranes, was not of much 
importance. This was because we did not study cell lysis per se. Instead, we were 
interested in the relative vigor of complement activation at various circumstances, and 
whether this was detected as function of C5b-9 insertion, cell lysis, or C5a liberation, is 
not expected to have changed the interpretation of the results. 
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6.5 FROM AIMS TO CONCLUSIONS 
Having discussed the results of Studies I-III in detail, it is finally time to look back at the 
original aims and to summarize the main results and conclusions (Fig. 31). 
Study I  aimet at describing the interactions between MDA adducts and the C-terminus 
of FH. It was shown that FH19-20 binds to MDA-modified proteins mainly through 
unspecific charge attractions and that a high surface concentration of MDA adducts is 
required for FH19-20 binding to occur. The question of whether MDA adducts could 
enhance FH-mediated complement regulation on a surface was not investigated. This 
is perhaps not relevant in the context of aHUS, since it is unlikely that extensive MDA 
adduct formation is involved in the pathogenesis of this disease. 
Study II aimed at answering the question of possible complement control by 
plasminogen. No significant role for plasminogen in complement regulation on cell 
surfaces could be shown. It is possible, however, that the protease form plasmin 
controls complement cascade propagation on cells in vivo. Thus, it remains to be 
studied, what is the reason for the association of plasminogen deficiency with aHUS: 
complement dysregulation or impaired fibrinolysis or something else? 
Study III  aimed at determining the role of sialic acid in FH function on cells implicated 
in aHUS. It was shown that, similar to erythrocytes, sialic acid is important for FH-
mediated complement regulation also on endothelial cells and platelets. Thus, the 
association of C-terminus mutations of FH with aHUS can be explained with impaired 
recognition of C3b on sialic acid-bearing self cells.  
Figure 31. Summary of the main results and conclusions of Studies I-III. 
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6.6 FINAL REFLECTION 
Evidence for the role of complement in the thrombotic microangiopathy aHUS was first 
reported in the 1970’s [283, 284]. Our knowledge of the pathogenesis of this rare 
syndrome has improved greatly ever since, but several aspects of the disease remain 
incompletely described. The work presented in this thesis brings us some steps 
forward in understanding the detailed mechanisms involved in aHUS pathogenesis. 
6.6.1 WHAT IS THE REASON FOR MALFUNCTION OF MUTANT 
FACTOR H? 
Mutations in the genes encoding proteins of the complement cascade have been 
demonstrated in 40-70% of patients with aHUS [282]. In some instances, the mutations 
enhance protein function. This is the case with, for example, factor B [235, 236]. More 
prevalent than gain of function is, perhaps, loss of function. Mutations that cause 
reduced protein activity in aHUS generally appear in regulatory proteins, like factor I 
[237, 238]. The most frequently mutated protein in aHUS is the regulator FH [282, 286-
288]. 
Mutations in FH cluster in the C-terminus of the molecule [290-292], that is, domains 
19-20. It is generally accepted that these mutations prevent FH from properly 
recognizing C3b deposited on self cells. Malfunction of FH with C-terminal mutations 
has mainly been attributed to erroneous binding of FH to heparin or C3b [90, 138]. 
However, disturbed interactions with either heparin or C3b are incapable of explaining 
FH dysfunction in most of aHUS patients with FH mutations.  
Impaired FH function due to mutations in FH19-20 is unlikely to involve plasminogen. 
For example, even though both FH and plasminogen interact with C3b, plasminogen 
does not affect FH binding to C3b  [251]. Furthermore, even though plasminogen was 
shown to enhance C3b inactivation by factors H and I [251], the effect was barely 
detectable and thus presumably insignificant. In line with this, we could not observe 
plasminogen to affect complement activation at the C3b step of the cascade either (SII). 
Most importantly, the aHUS patients deficient in plasminogen were not reported to 
carry mutations in the gene of FH [344]. Thus, the reason for mutant FH malfunction is 
not expected to involve plasminogen. 
Disturbed recognition of MDA adducts was initially hypothesized to explain association 
of C-terminus mutations of FH with aHUS. However, FH19-20 binding to MDA adducts 
was observed to necessitate a surface with a high density of MDA adducts (SI), which 
was considered unlikely to be found in vivo. More importantly, similar to the case with 
heparin, some aHUS mutations were observed to increase FH19-20 affinity for MDA-
BSA whereas other mutations decreased the binding (SI). This means that the MDA 
adduct binding data did not parallel with functional complement activation data (SIII). 
Thus, impaired MDA adduct recognition due to FH mutations is also unlikely to be 
involved in aHUS. 
Investigation of the role of sialic acid in FH-mediated complement regulation on self 
cells finally resulted in a general explanation for mutant FH dysfunction in aHUS. It was 
observed that mutations in the C-terminus of FH impair the ability of this regulator to 
simultaneously bind sialic acid and C3b on three types of cells affected in aHUS (SIII). 
Unlike with heparin, C3b [90, 138], or MDA adducts (SI), the pattern of mutant FH19-
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20 binding to sialic acid (in the context of C3b) was observed to parallel the mutant 
inhibition pattern of functional complement activation assays (SIII). Furthermore, the 
mutant binding pattern exactly fulfilled earlier structural predictions made of FH19-20 
interactions with sialic acid and C3b [58]. Thus, disturbed sialic acid recognition during 
complement attack was concluded to provide a general explanation for aHUS 
pathogenesis in patients with C-terminus mutations of FH. 
The proposed “sialic acid theory of aHUS” should not, however, be taken as the final 
truth. Namely, even though applying to most cases, the theory does not quite explain 
the association of every C-terminus mutation of FH with aHUS. For example, the 
mutation T1184R was not observed to affect FH19-20 binding to cells bearing sialic 
acid and C3b (SIII). So, how can we explain the association of the mutation T1184R 
with aHUS? 
 
6.6.2 HOW IS aHUS TRIGGERED? 
Individual mutations in complement genes are not sufficient to cause aHUS. Disease 
onset requires an additional triggering event [363]. This is most often an upper 
respiratory tract infection or diarrhea/gastroenteritis, although other infections as 
well as pregnancy and drugs have also been reported [282]. Considering the 
importance of the triggering event as a disease precipitating cause, it is curious that so 
little seems to be known about it. The aHUS-associated drug cyclosporine was shown 
to induce release of complement-activating microparticles from endothelial cells [349], 
but it remains to be studied whether this mechanism applies with other triggers. 
Human plasma contains natural antibodies that recognize MDA epitopes [164-174]. 
These immunoglobulins are of classes known to activate complement through the 
classical pathway [169]. Thus, the triggering mechanism of aHUS could involve 
appearance of MDA adducts on surfaces exposed to blood. The threshold concentration 
of anti-MDA-adduct antibodies necessary for initiation of complement activation is 
unknown, but at least binding of the natural anti-MDA-adduct antibodies is expected 
to require a lower density of surface MDA adducts than what was observed necessary 
for FH19-20 (SI). 
The events triggering aHUS in patients with plasminogen deficiency were not reported 
[344], but this information would be very interesting. Namely, plasminogen deficiency 
as a sole abnormality causes ligneous conjunctivitis [388], which hints to other defects 
besides lack of plasminogen to be necessary for tipping disease progress towards 
aHUS. Even though we could not show a role for plasminogen in complement 
regulation (SII), the presence of complement gene mutations in aHUS patients with 
plasminogen deficiency suggested involvement of complement. Knowledge of the 
triggers and confirmation of the role of complement in plasminogen-deficiency 
associated aHUS could help us solve the triggering problem in general.  
Finally, our observation of the necessity of surface sialic acid for FH regulation (SIII) 
allowed us to posit new hypotheses on the aHUS-triggering mechanism for future 
testing. As described in detail above, a triggering event could lead to reduced 
expression of sialic acid on cell surfaces and thereby impair FH-mediated protection of 
cells from complement. This proposition is not, however, without problems. Namely, 
some mutations completely prevent FH from interacting with sialic acid (SIII). 
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Therefore changes in cell surface sialic acid concentration are not expected to affect 
function of these mutant FH molecules. Thus, a trigger affecting sialic acid expression 
is capable of explaining the triggering effect only in some cases of aHUS.  
 
 
6.6.3 IS THERE A POINT OF CONVERGENCE? 
The first mutations associated with aHUS were those located in the gene of FH [285]. 
Subsequently, nucleotide changes in several other complement genes have also been 
linked to the disease [282]. With roughly two thirds of the patients displaying 
complement abnormalities, aHUS is currently viewed as to result from dysregulated 
activation of the alternative pathway of complement.  
Besides complement factors, proteins relevant to coagulation cascade function have 
started to become linked to aHUS. The anticoagulatory protein thrombomodulin was 
shown capable of regulating complement activation, and thus the association of 
thrombomodulin mutations with aHUS could be attributed to reduced complement 
control [229]. In aHUS patients with plasminogen deficiency, on the other hand, the 
question of complement involvement remains unclear (SII, [344]). Finally, several 
aHUS patients have been reported to carry mutations in the gene of diacylglycerol 
kinase epsilon (DGKε) [347]. The enzyme DGKε is involved in increasing production of 
both pro- and anti-inflammatory factors, and even though the details remain unclear, 
the net effect of DGKε seems to be to prevent protein kinase C from driving cells 
towards a prothrombotic state [347]. Loss of DGKε function in endothelial cells was 
later observed to cause, for example, increased TF expression and apoptosis, but not to 
exacerbate complement activation on cells [348].  
If we consider the whole spectrum of mutant proteins associated with aHUS, we notice 
that at one extreme, there are the dysfunctional complement factors of serum. In the 
middle, the mutations presumably affect both the complement and coagulation 
cascades. At the other extreme, loss of control over intracellular signaling results in a 
procoagulatory state of cells, but complement dysregulation is not involved. This raises 
the following question: how can such divergent abnormalities as impaired FH binding 
and reduced DGKε-mediated inhibition of cell signaling lead to the same outcome, the 
disease aHUS? Do the pathogenic mechanism converge at some point? Could C5a 
liberated during complement activation, for example, lead to augmented protein kinase 
C function similar to that reported for loss of DGKε function? Or is it that different 
genetic causes only lead to the same outcome (the manifestation of aHUS) but through 
completely different pathogenic mechanisms? 
To conclude with the terms relevant to this thesis: if a trigger induces exposure of 
complement-activating MDA adducts to blood, and mutant FH fails to protect cells from 
the ensuing complement attack due to impaired sialic acid recognition, at what point 
does the disease mechanism in this aHUS case converge with the pathogenic events 
observed in a patient with plasminogen deficiency?  
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